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The rates for colon and rectal cancer (CRC) are increasing at an alarming rate in 
individuals under the age of 50. Because of this, The American Cancer Society gave a 
qualified recommendation for average risk adults to initiate colorectal cancer screening at 
age 45. This recommendation challenges the long-standing guidelines to begin screening 
at age 50. If adopted, this would add approximately 19 million Americans to the eligible 
screening pool. This shift in thinking is controversial and researchers and guideline 
recommending organizations have responded with caution. While a large body of 
literature on CRC screening exists, very few studies have focused on individuals under 
the age of 50 due to the previous, relative consensus on guidelines. Because the 
uncertainty and relative equality of screening strategies and outcomes, patients under 50 
and clinicians making decisions about screening should consider a shared decision-
making framework. In this dissertation, I explored differences in several constructs of the 
shared decision-making framework by age (<50 & ≥50) using a sample of 579 
participants drawn from MTurk, a global crowdsourcing workforce that is often utilized 
for research studies. In paper 1, I evaluated knowledge of CRC risk factors and symptoms 
and found that age moderated the relationships between several independent variables 
including perceived likelihood of getting cancer and numeracy with total knowledge 
scores. In paper 2, I explored preferences for colorectal cancer screening strategies using 
a multicriteria decision analysis technique called the Analytic Hierarchy Process and 
found that participants <50 preferred colonoscopy more often than those ≥50. In paper 3 I 
used multinomial logistic regression and found that participants <50 preferred the shared 
and passive role compared to the active role for deciding whether to get screened and 
deciding which strategy to use more often than participants ≥50. These findings will act 
as a foundation for future work if it becomes necessary to incorporate younger people 
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Chapter 1: Problem Statement  
1.1 Problem Statement  
Colorectal cancer (CRC) is a leading cancer control priority because it has the 
third highest incidence of all cancer sites in both sexes.1,2 The overall incidence of and 
mortality from colorectal cancer is declining in the United States and across the globe 
primarily due to the public health effort to improve age appropriate, guideline-based 
screening.3–6 Improved treatment modalities and changes in risk factor exposure also 
account for some of the decreases in CRC incidence and mortality.4 However, the 
incidence of colon and rectal cancer is increasing in younger individuals.7,8 In adults 50 
years and younger, there was a 51% increase in CRC incidence between 1994 and 2014. 
For rectal cancer, incidence rates doubled between 1991 and 2014 in people age 20 to 49 
(2.6/100,000 to 5.2/100,000).3  
Several key papers in the field have called for reconsidering the age to initiate 
CRC screening for several reasons: (1) the ‘upswing’ in CRC incidence in younger 
people (2) the fact that these cancers are often diagnosed at a later stage, (3) 
misattribution of symptoms that delays diagnosis and (4) the favorable benefits versus 
burdens of population based screening in people 45-49.8,9 Most notably, the American 
Cancer Society (ACS) recently updated their recommendation to initiate screening at 45 
years old with a ‘qualified’ recommendation.3 A qualified recommendation designates a 
recommendation where clear evidence for benefit exists but there is less certainty about 
the balance of the harms, benefits, patient values and preferences.3 This updated 
recommendation is based on microsimulation models indicating the effectiveness 
(benefits versus harms) of screening in younger individuals,10 epidemiologic data 
showing the upwards trend in disease burden,7,8 and the expectation that screening will 
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perform similarly well in adults ages 45 to 49 as it does in adults 50 years or older. 
However, guideline recommendations from other sources, such as the United States 
Preventive Services Task Force (USPSTF), remain supportive of the position to initiate 
age-based screening at age 50 for average risk adults.† People are considered average risk 
if they do not have: a personal or family history of CRC, a history of an inflammatory 
bowel disease, inherited syndrome, or personal history of radiation to the abdomen for 
other cancer treatment.11 This shift in thinking about the appropriate age to begin 
guideline-based screening for CRC is impactful because, if adopted, this recommendation 
would add approximately 19 million individuals to the eligible screening pool.12,13 As 
such, researchers, clinicians, and other experts in the field have debated such a change 
and have called for more research to be conducted on the consequences of this shift at 
multiple levels. 3,13–16 Both clear benefits and harms to screening in younger individuals 
exist indicating the potential need for a shared decision-making process among 
physicians and patients that takes into account knowledge, preferences for screening 
tests, desired role in the decision-making process and their self-efficacy for making 
medical decisions. Research exploring CRC screening in younger people is timely for 
several reasons: (1) The shifting disease burden of CRC to younger individuals; (2) 
updated recommendations about screening in people under 50; (3) evidence indicating 
that there is a high level of misunderstanding in younger people about screening tests for 
colorectal cancer and knowledge of risk factors for colorectal cancer; and (4) recent calls 
for additional research in this area by experts.  
† This dissertation project was defended on October 19th, 2020. On October 27th, 2020 
the USPSTF released a draft recommendation statement incorporating those age 45-49 
into their recommendations. This change does not impact the results of this study but all 
subsequent references to the USPSTF should be interpreted with this update in mind. 
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1.2 Guiding Model and Conceptual framework 
Clearly, the rates of CRC are rising in younger individuals. However, it is also 
clear that screening in people under the age of 50 is not without uncertainty around 
potential harms or risks and additional burden. Screening in this younger cohort is i) 
costly, ii) it could lead to over-screening for individuals who are actually at lower risk or 
those who have false positive results, iii) it has the potential for harms, especially with 
colonoscopy (e.g., perforation, bleeding, or infection), and iv) is associated with a high 
burden with respect to time and potential resources. Shared decision-making17 is “at its 
core… an interpersonal, interdependent process in which the health care provider and the 
patient relate to and influence each other as they collaborate in making decisions about 
the patient’s health care.”18 The USPSTF defines shared decision-making as a process of 
decision-making by a patient and clinician with the goal of an informed and joint decision 
in which the patient: 
“…(1) understands the risks or seriousness of the disease or condition to be 
prevented; (2) understands the preventive service, including the risks, 
benefits, alternatives, and uncertainties; (3) has weighed his or her values 
regarding the potential benefits and harms associated with the service; and 
(4) has engaged in decision-making at a level at which he or she desires and 
feels comfortable.”19 
Shared decision-making also assumes that both the provider and the patient have 
access to and an understanding of the available evidence to make informed decisions. 
Shared decision-making is most appropriate when there is a decision to be made between 
treatment options with similar outcomes or when there is a condition of high uncertainty 
4 
between options and when the decision is highly ‘preference-sensitive’.18,20–22 Colorectal 
cancer screening in individuals under the age of 50 satisfies these conditions. For such 
situations, there are two decisions to be made: whether to screen and if so, which 
screening test to use. The decision of whether to screen takes into account the benefits of 
both screening (early detection and peace of mind) as well as potential harms of 
screening (false positives, false negatives, costs, and the potential for injury), patient 
preferences, and burden or costs. Unique to the younger patient population is the 
uncertainty and disagreement amongst guidelines about the appropriate timing for when 
to initiate screening. Furthermore, the patient and provider face the decision of which 
screening strategy to use. Availability of screening options for CRC are in a unique area 
of relative equipoise where there is a balance between test-features, risks associated with 
the procedures, and cancer detection outcomes. This is evidenced by recommendations 
that any CRC screening is preferred over none and the American Cancer Society 
explicitly not endorsing a single strategy over others. 3 In this study, I will use the shared 
decision-making framework with constructs adopted from Christy and Rawl (Figure 1). 22 
Because this study is using a sample from the general population, who have not been 
screened, I will focus on patient factors that may influence the shared decision-making 
process as well as the antecedents to SDM that are outlined by the SDM literature: 
knowledge, preference, and desired role in decision making. These three characteristics 
of an individual could influence a clinical interaction that would occur when a patient is 
discussing colorectal cancer screening with a doctor. These patient level characteristics 
are hypothesized to be influenced by each other but also by other patient- variables, such 
as age. This study recognizes the importance of the provider as well as the medical 
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system, however, these characteristics would be more appropriate to assess in a setting 
where a decision is being made.   
6 
Figure 1: Shared decision making in colorectal cancer screening 
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1.3 Research Questions  
In this dissertation project, I will address the following research questions centered 
around the shared-decision-making framework for colorectal cancer screening in 
individuals under 50: 
RQ1: Are people under age 50 able to correctly identify risk factors of CRC? 
Rationale: To make an informed decision about colorectal cancer screening, a patient 
must have adequate information to initiate a discussion with their doctor. Additionally, an 
important part of the shared decision-making process is assessing the patient’s current 
knowledge.21 Recent work by Mueller et al. (2019)24 indicates that younger people are 
confused about the types of screening tests available for CRC and their overall risk of 
developing the disease. Questions about whether people under 50 can identify risk factors 
to initiate a discussion with their doctor remain unanswered.  
RQ2: What screening strategy do individuals under 50 prefer and on what are these 
preferences based?   
Rationale: A critically important factor to shared decision-making is that the decision is 
based on preferences. The type of screening test that people prefer fall into 2 major 
categories: a structural exam (i.e. colonoscopy or flexible sigmoidoscopy), or a stool-
based exam. Preferences for these tests are highly dependent and the literature on which 
test is preferred by individuals 50+ is inconsistent. Almost no work has been done to 
explore preferences in people under the age of 50. Understanding which tests people 
under the age of 50 prefer will reveal whether there are strongly held preferences that 
clinicians should be aware of when working within the shared decision-making 
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framework. Also, an understanding of what the factors affecting these preferences are 
will give clinicians more information when describing, highlighting, and creating tools to 
facilitate decision-making in patients, by focusing on the most important strategy 
attributes. 
RQ3: When making CRC screening decisions, what level of control (role preference) 
do people under 50 prefer and do they feel confident in their ability to make 
decisions? 
Rationale: When considering decision-making for colorectal cancer screening, it is 
important to consider that some individuals may not be receptive to shared decision-
making and want to follow a paternalistic approach where the doctor leads or guides 
decisions based on their own preferences and clinical experience. Or, vice versa, some 
patients may prefer to be the primary driver of decisions.  Reviews on the topic show 
variable interest by patients in desire to participate in shared decision-making.25 Evidence 
suggests that these preferences may vary by features including age, education, health 
literacy, and income.25 Evidence for these preferences among younger people to engage 
in shared decision-making in this context, and whether these preferences are related to 
other patient-level variables will allow clinicians to engage patients at their desired level. 
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1.4 Definition of Terms  
Colorectal cancer For this dissertation colorectal cancer (CRC) will be considered 
any primary cancer originating in the colon or rectum. While 
these two cancers are distinguishable, mortality statistics are 
often grouped together 26 due to misclassification on death 





Colorectal cancer screening refers to systematic screening of the 
asymptomatic, general public. This is distinct from diagnostic 
colonoscopy, which is used in individuals who are symptomatic 
or otherwise displaying signs of disease and surveillance 
colonoscopy, which is used to follow-up previously diagnosed 
CRC. Colorectal cancer screening is usually initiated beginning at 
a specific age, according to guidelines outlined by professional 
and government entities (see section 2.7). There are several 
colorectal cancer screening tests that are recommended and 




Self-efficacy is a health behavior construct that represents one’s 
confidence in their ability to perform a behavior.27 In this 
dissertation, self-efficacy is for decision-making, or one’s ability 
to carry out the necessary steps to perform a behavior. For 
operationalization of decisional self-efficacy see Appendix A (pg. 





Activated patients “are patients who have the motivation, 
knowledge, skills, and confidence to make effective decisions 
about their health”29. Higher levels of patient activation are 
associated with improved health and health related behaviors 




See section 1.2 for a full discussion of shared decision-
making. USPSTF defines shared decision-making as a process of 
decision-making by a patient and clinician with the goal of an 
informed and joint decision in which the patient “…(1) 
understands the risks or seriousness of the disease or condition to 
be prevented; (2) understands the preventive service, including 
the risks, benefits, alternatives, and uncertainties; (3) has weighed 
his or her values regarding the potential benefits and harms 
associated with the service; and (4) has engaged in decision-
making at a level at which he or she desires and feels 
comfortable.”19 
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Chapter 2 Literature Review  
2.1 Colorectal Cancer as a Public Health Issue 
Colorectal cancer is a cancer of the bowel that occurs in either the large intestine 
(the colon) or the rectum. The lifetime risk of developing CRC is approximately 1/23 
(4.4%) for men and 1/25 (4.1%) for women.30 Currently, within the United States there are 
around 1.3 million people living with CRC.31 CRC accounts for approximately 8.3% of 
new cancer cases and 8.4% of all cancer deaths in the United States.30 Between 2008-2014, 
the overall 5 year survival rate for CRC was 65%. For the 39% of people diagnosed with 
localized disease, the 5 year survival is 90%. 30,32 
Reduction of CRC incidence and mortality is a priority for the United States public 
health system. Several public health entities have set goals for CRC. For this decade,  
Healthy People 2030 set goals to reduce the CRC death rate from 13.4/100,000, measured 
in 2018, to 8.9/100,00033 and to increase the proportion of adults who receive colorectal 
cancer screening based on the most recent guidelines from 65.2% to 74.4%.34   The 
National Colorectal Cancer Roundtable has set a goal for 80% of adults aged 50 and older 
to be getting regular screenings for CRC referred to as the “80% Pledge”.35 Reaching this 
goal would achieve a reduction in incidence by 33% and mortality by 22% by 2030.36 
Overall, this would lead to avoiding 21,000 CRC deaths per year for a total of over 200,000 
deaths avoided by 2030. However, the costs of achieving this goal were not calculated for 
this study, rather, the authors focused on only incidence and mortality reduction of the 80% 
goal.  
Significant progress has been made in the last decade towards tackling CRC as a 
public health issue and several goals have been achieved. The Healthy People 2020 
objectives to reduce the CRC death rate from 17.1 deaths/100,000 population to 14.5 was 
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achieved.  Nationwide, more people are being screened for CRC every year. In 2018, 
65.2% of people over the age of 50 were up-to-date with their colorectal cancer screening.37 
However, there are many issues and research questions surrounding screening for 
colorectal cancer that have yet to be unraveled.  
2.2 Etiology  
Polyps 
Similar to other cancers, the hallmark feature of CRC is unregulated and 
uncontrolled cell growth and division. Colorectal cancer occurs from malignant cell 
overgrowth in the parts of the large intestine known as the colon or rectum. Development 
of CRC begins as noncancerous growth or a precancerous lesion, called a polyp.38 
Precancerous polyps, also known as adenomas or adenomatous polyps, arising from 
glandular cells found in the colon and rectum, are the most common precursor to CRC.38,39 
Colonic polyps are found in up to 30 to 40% of people by age 60 but only ~10% of polyps 
progress to cancer.40,41 However, over 95% of colorectal cancers begin as adenomatous 
polyps.41 Polyps under 10mm in size are considered ‘small’ and polyps <5mm are 
considered diminutive or minute.42 Polyps of greater size generally confer an increased risk 
of CRC compared to smaller polyps and advanced polyps generally grow more rapidly than 
non-advanced.43 Polyps are often asymptomatic but can cause rectal bleeding, and rarely, 
symptoms of partial bowel obstruction.41   
Development of polyps into colorectal cancer 
 Adenomatous polyps can develop into cancer over a period of 10 to 20 years. 2,39 
Colorectal cancer can be found in both the proximal colon (ascending or transverse colon) 
or in the distal colon (descending and sigmoid colon).38 Colorectal cancer is often staged 
using the American Joint Committee on Cancer (AJCC) system that assesses the size of 
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the tumor and whether and how far the tumor has grown into the colon or rectal wall (T); 
whether the cancer has spread to nearby lymph nodes (N); and whether the cancer has 
metastasized to distal lymph nodes or other organs (M). This system is often referred to as 
the TMN system. 44 
2.3 Colorectal Cancer Epidemiology 
CRC Incidence and Mortality 
Colorectal Cancer (CRC) has the third highest incidence of all cancer sites with a 
projected estimate of 104,610 cases of colon and 43,340 cases of rectal cancer to be 
diagnosed in 2020. 1,2,7 Most cases of CRC occur in individuals over the age of 50 and the 
median age that people are diagnosed is 68.45 Incidence for colon cancer are similar for 
both men and women with a 2020 projected estimate of 52,340 cases in men and 52,270 
cases in women.1,26,46 However, incidence is markedly higher for rectal cancer in men with 
25,960 projected cases in 2020 versus 17,380 in women.1,26,46  For mortality, colorectal 
cancer is the second leading cause of cancer death in the United States and, in 2020, 53,200 
individuals are projected to die from CRC.1   Data for colon and rectal cancer mortality are 
often combined because a large proportion of rectal cancer cases are misclassified as colon 
cancer.2,26 Significant disparities exist by race for colorectal cancer incidence and mortality 
by race and ethnicity. Black men have the highest incidence (58.3/100,000) and mortality 
rates (25.9/100,000) compared to Asian women who have the lowest incidence 
(27.8/100,000) and mortality (8.8/100,000). CRC incidence and mortality varies widely by 
state and region in the United States. Between 2010-2014 Kentucky had the highest age 
adjusted incidence rate for CRC of 50/100,000 whereas Utah had the lowest at 
31.4/100,000. Incidence and mortality rates for CRC have steadily decreased47 since the 
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mid-1970s due to increased awareness of the disease, screening uptake, changing of risk 
factors and improved treatment.3,4  
2.4 Screening Modalities 
Several methods are used to screen for CRC. Some of these strategies are also 
used for surveillance for colorectal polyps or for diagnosis and workup of symptoms.  
Generally, these methods can be thought of as stool-based tests and structural exams that 
allows for direct visualization, such as colonoscopy or flexible sigmoidoscopy. The 
American Cancer Society recommendations include offering patients the opportunity to 
choose which strategy they prefer based on availability and preference for test features.3 
Each strategy has a specified screening interval, or the length of time that an average risk 
individual should repeat testing after a ‘normal’ screening result. A ‘positive’ result for 
a screening test that is a non-colonoscopy exam is generally followed up with a 
colonoscopy exam, that allows for therapy of colon polyps or confirmation of CRC.48 
In the following sections, I will review only tests that are endorsed by the American 
Cancer Society’s 2018 guidelines (Section 2.7), however, lesser used tests are available 
and generally have less evidence to support their use or are explicitly not recommended. 
Stool-Based Strategies 
Fecal Occult Blood Test (FOBT) 
FOBT, also known as gFOBT detects hidden blood in the feces that can come 
from the upper or lower GI tract.48 This test is simple to use and has been shown to 
reduce CRC mortality. 49 In one randomized study of 46,551 participants, annual FOBT 
reduced 13-year CRC mortality by 33%50 However, a positive result requires a moderate 
amount of blood and so the FOBT is not a very sensitive test, especially for advanced 
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adenomas.51,52 One-time FOBT testing may have sensitivity lower than 50% so the 
screening interval for this strategy is one year. 51,52 Because of the low sensitivity of 
FOBT, its poor ability to detect advanced adenomas, and sensitivity to dietary and 
medication restrictions such as vitamin C, red meats, and anti-inflammatory drugs, it has 
been replaced by FIT tests in many clinical settings. 53 
Fecal Immunochemical Test (FIT) (iFOBT) 
The fecal immunochemical test (FIT) identifies hemoglobin in the stool that could 
indicate bleeding from a polyp or from CRC. It is more specific than FOBT to 
hemoglobin arising from the lower gastrointestinal (GI) tract making it a better test for 
detecting CRC.54 In a study conducted in Taiwan, Chiu, et al. (2015) estimated a 62% 
mortality reduction in those participating in biennial FIT testing versus those who 
received no screening when participants were followed up for a maximum of 6 years. 
55FIT is also advantageous over FOBT because there are no dietary or drug restrictions 
and it has higher rates of participation and patient acceptance.53,56,57 Like FOBT, the 
screening interval for the FIT strategy is every year.  
Pooled data presented in one study from 113,360 participants with 437 confirmed 
CRC cases indicated that the sensitivity of FIT was approximately .79 (95% CI: 0.69-
0.86) and  specificity was .94 (95% CI:0.92-0.95).58 Another, more recent, meta-analysis 
found that CRC sensitivity values for FIT tests ranged from .71 to .91 and specificity 
values ranged from .90 to .95. For advanced adenomas, sensitivity estimates ranged from 
.25 to .40 and specificity estimates from .90 to.95.59 However, the authors noted that true 
sensitivity and specificity values are difficult to estimate due to the multiple FIT tests 
available on the market and different thresholds for positive results that can be used.59   
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Fecal/Stool DNA (Cologuard) 
Like most cancers, CRC begins as an accumulation of genetic changes. DNA 
markers for these changes can be detected by fecal DNA tests when they are shed by the 
cancerous or precancerous lesions into the colorectal tract. 54,59,60 Cologuard is currently 
the only stool DNA test to be approved by the FDA. Cologuard works by detecting fecal 
blood using FIT in addition to DNA biomarkers related to 3 genes (KRAS, BP3, and 
NDRG3).   
Imperiale and colleagues (2014) reported that fecal DNA testing using Cologuard 
significantly improved testing sensitivity for CRC when compared to a FIT group (92.3% 
vs 73.8%) as well as for those with advanced precancerous lesions (42.4% vs 23.8%).59 
This increase in sensitivity significantly reduced specificity thus increasing the false 
positive rate. Specificity for the Cologuard group, confirmed by negative results on a 
colonoscopy, was 89.8% compared to 96.4% in the FIT group. 59  Because of the 
increased sensitivity, The American Cancer Society recommends the screening 
interval to follow up normal screening to be every 3 years when using a stool DNA.3 
However, when compared to colonoscopy every 10 years, stool DNA test every 3 years 
was not recommended for individuals under 50 by modeling studies that were conducted 
to inform the American Cancer Society recommendations (Section 2.7) based on the 
benefits (life years gained) versus burdens (number of colonoscopies due to false 
positives) of this screening strategy.10  
According to the Cologuard website, for individuals ages 50 to 85, 94% of 
patients have no out of pocket costs for screening. 61 However, the most recent list price 
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of Cologuard is $649, which would likely be the out of pocket costs for an individual 
under the age of 50 who seeks screening.62 
Structural Exams 
Sigmoidoscopy and Colonoscopy 
Sigmoidoscopy and colonoscopy are both structural visualization exams during 
which an endoscopist inserts a scope through the anus to view the rectum and colon.  
During both exams, cancerous lesions and polyps can be visualized and biopsied or 
removed. There are several key differences between sigmoidoscopy and colonoscopy. (1) 
A colonoscopy can visualize the entire colon and rectum, while sigmoidoscopy can only 
visualize the rectum and the lower sigmoid colon. (2) Flexible sigmoidoscopy requires 
less complicated bowel preparation and can often be completed with a laxative or enema. 
(3)  Sigmoidoscopy is a less invasive procedure and thus does not usually require as 
much sedation for patients to tolerate the procedure as colonoscopy. (4) The screening 
interval for sigmoidoscopy is 5 years while normal colonoscopy screenings should be 
followed up every 10 years.48 There are risks associated with both procedures including 
bleeding, pain, and perforation of the colon, which can lead to death. The risk of bowel 
perforation is approximately double in colonoscopy (1.96/1,000) than in sigmoidoscopy 
(.88/1000).63 Despite these risks, the use of sigmoidoscopy has declined significantly, and 
as of 2010, only 2.5% of US adults age 50 to 75 report sigmoidoscopy screening within 
the recommended interval while 60% report colonoscopy screening. 3 
Both sigmoidoscopy and colonoscopy are associated with reduction of colorectal 
cancer mortality. Pooled data from the 2016 USPSTF† evidence report (pooled 
n=458,002) indicated that sigmoidoscopy was associated with an approximately 27% 
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reduction in 11 to 12 year CRC mortality compared to no screening, however, this 
mortality reduction was limited to CRC in the distal colon due to the visualization range 
of sigmoidoscopy.64 Mortality reduction for CRC is even greater for colonoscopy. One 
study, by Nishihara, et al. reports hazard ratios of .47 (95% CI: .29-.76) for proximal 
cancer, .18 (95% CI: .10-.31) for distal cancer, and an overall hazard ratio of .32 (95% 
CI: .24-.45) over 24 years for the group receiving one or more colonoscopy versus no 
screening.65 Ko and colleagues (2019) conducted a retrospective study using the SEER 
database and found that sigmoidoscopy was associated  with a 35% reduction in CRC 
mortality while screening colonoscopy was associated with a 74% reduction in 
mortality.66 Similar to other studies in the literature, they also found that reduction in 
mortality for sigmoidoscopy was only for cancers in the distal colon.  
Computed Tomography Colonography (CTC) (Virtual Colonoscopy) 
CTC screening is a procedure that utilizes an x-ray to take pictures of the colon 
and rectum. The compilation of these images allows a physician to visualize the inside of 
the colorectal tract and see polyps or cancerous lesions.67 CTC procedures are generally 
performed in outpatient radiology settings but can be performed selectively in hospital 
settings for individuals who are considered high risk for colonoscopy.68 CTC use in the 
United States is becoming more common, although use varies by geographical location 
with rates as low as 2.38/100,000 in rural areas and as high as 6.67/100,000 in urban 
areas.69 CTC does not require the patient to be sedated and has very low risk because it is 
noninvasive; however, it does require bowel preparation similar to a standard 
colonoscopy for proper visualization of the colon.67 An abnormal result is followed up 
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with a colonoscopy so that polyps or other lesions can be removed and diagnosed. The 
recommended screening interval for a strategy utilizing CTC is 5 years.3 
Evidence for CTC effectiveness as a screening strategy is low compared to other 
screening strategies but growing. One meta-analysis that included 49 studies with a 
cumulative sample size of 11,151 concluded that sensitivity for CTC to detect colorectal 
cancer was as high as 96.1%. 70 Specificity values were not calculated in this review 
because, in many studies, benign polyps are included as true-positives making it 
impossible to estimate the true negative, and false positive values required for specificity 
calculations.70  However, other studies indicate that CTC has a specificity of between 89-
91%.64 Sensitivity values for polyps have been calculated in a large multi-center study as 
approximately 94% for polyps >10mm, 94% for >8mm, and 89% for polyps >6mm. 
Corresponding specificity values for these polyp measurements were 96%, 92%, and 
80%.71 
2.5 The Rising Risk for CRC in Younger People 
Population-based analyses indicate that 11-12% of incident CRC cases in the 
United States occur in individuals under age 50.72 Recent, epidemiologic studies using 
the Surveillance, Epidemiology, and End Results Program (SEER) database indicate that 
the incidence of both colon and rectal cancers in the United States is rising at a 
concerning rate in individuals under the age of 50.8,73–75 This program is supported by the 
National Cancer Institute and collects data from all cancer cases reported in a nationally 
representative sample that spans 19 geographic regions and 12 states in the United 
States.76  
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A study conducted by Siegel et al (2017)8 is unique in presenting these findings 
because of her use of age-period-cohort modeling (Figure 2). This technique allowed her 
to show that the differences seen in both colon and rectal cancer are due primarily to 
cohort effects, described by Siegel as changes that vary by generation like health 
behaviors, rather than period effects which are factors that influence all ages such as 
changes in medical practice.8  She found age adjusted relative risks for those born in the 
1991 birth cohort were 2.40 for colon and 4.32 for rectal cancer when comparted to the 
lowest risk birth cohort, or those born circa 1950.8 This study also found that between 
approximately 1985 to 2013, rates of colon cancer decreased in adults 55+, but increased 
Figure 2: Age adjusted incidence trends for colon and rectal cancer drawn from Siegel, et al. 2017 
supplemental materials 
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by 2.4% per year in adults age 20 to 29, and by 1% per year in adults age 30 to 39. In 
adults age 40 to 49, rates of colon cancer started to increase by about 1.3% per year 
starting in the mid-1990s. These increasing rates were accounted for primarily by tumors 
in the distal colon. Incidence rates for rectal cancer are increasing even more rapidly than 
for colon cancer. Rates increased by 3.2% per year for adults age 20 to 29 between 1974-
2013 and similarly from 1980 for adults 30 to 39.  For adults age 40 to 49, rates increased 
by 2.3% per year starting in the mid-1990s. Rates of rectal cancer have been steadily 
decreasing in adults 55+ since around 1980. Additionally, Siegal argues that the 
increasing rates in younger cohorts are inconsistent with screening or lead time biases. 
These biases are seen when incidence rates are skewed by increased uptake in screening, 
which enables us to detect cancers at younger ages. She notes that rates are increasing 
most rapidly for the youngest cohorts who are also those that are least likely to be 
screened. Moreover, rates have risen similarly for both early and late stage cancers.8 
Interestingly, increases in both colon and rectal cancer have been documented in other 
countries across the globe.5,77  
2.6 Guidelines on When to Initiate Age-Based CRC Screening 
A number of policy recommending organizations have released evidence-based 
guidelines and recommendations for colorectal cancer screening. These recommendations 
provide guidance for clinicians, researchers, and patients as to the most effective 
strategies and ages for colorectal cancer screening. A summary table of guidelines, drawn 
from Robertson and Ladabaum (2019) can be found in Table 178  
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Table 1: Summary of Current US Colorectal Cancer Screening Guidelines adapted from Robertson and 
Ladabaum (2019) 
Guideline Year Starting 
Age 
Stopping age Sex Race Endorsed 
Tests 
Preferred test 
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Updated American Cancer Society (ACS) Recommendations 
In 2018, the American Cancer Society (ACS) updated their guidelines for CRC 
screening. In contrast with most guidelines, the ACS recommended that adults aged 45 or 
older with average risk of CRC begin regular screening with either a high sensitivity 
stool-based strategy or a structural (visual) exam depending on the individual’s 
preference and test availability. 3 The recommendation to begin screening at age 45 was 
made because of the upswing in CRC incidence in younger age groups previously 
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mentioned. This recommendation is deemed as a qualified recommendation due to 
the lack of direct empirical data pertaining to screening in individuals under age 50. 
3 However, modeling studies indicate a favorable benefit-burden balance in that the 
number of life years gained through reduced CRC incidence and mortality by beginning 
screening at age 45 was acceptable when compared to the increase in overall number of 
colonoscopies performed by beginning at the younger age (Figure 3).   
 
2.7 Debate Over Recommendations 
Since the qualified recommendation from the American Cancer Society to lower 
the age to initiate screening to 45 in May of 2018, several  commentaries, editorials, and 
empirical research articles have been published that debate this shift. The contrasting 
viewpoints from researchers and practitioners that are summarized in the following 
sections are essential to state so that the controversy in the field is recognized and future 
research can address these issues. 
 
Figure 3: Life years gained for available screening tests at different ages of initiation 
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The cost of shifting recommendations 
Much of the concern that experts in the field have noted focuses on the costs 
associated with adding approximately 19 million people between the ages of 45 to 49 into 
the eligible screening pool. In an editorial written by Bretthauer, et al. the authors 
estimated this cost using CRC incidence and mortality metrics3,31 and the assumptions 
that screening in this age group will reduce CRC risk by 50% with a cost of $250 per 
person using a mix of colonoscopy and FOBT. Roughly, the cost to prevent 900 CRC 
deaths annually would be approximately $5.5 billion or $6.1 million dollars per death 
averted through universal screening in this age group. 83 While these assumptions are 
overly simplifying, this puts into perspective how costly a push towards universal 
screening in this age group might be. Some authors argue that some of these costs could 
be mitigated through precision screening, rather than universal screening. Precision 
screening would involve using genetic, lifestyle, and environmental factors, along with 
previous screening experience, to categorize people into appropriate risk categories for 
early screening.84  
 Related to this, some researchers worry that important and limited resources may 
be diverted away from older groups who remain at the highest risk, regardless of the 
groups’ overall decline in incidence and mortality.13 A recent cost-effectiveness analysis 
estimated the costs of changing recommendations from 50 to 45 required an additional 
758 colonoscopies and averted approximately 4 CRC cases and 2 CRC deaths in 1000 
people, for a total gain of 14 quality of life years (QALYs) costing $33,900 for each 
QALY gained. While this was deemed cost effective by the authors, for the same number 
of additional colonoscopies, 231 unscreened 55-year-olds or 342 unscreened 65 to 75-
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year-olds could have been tested for 13 to 14 averted CRC cases and 6 to 7 CRC deaths. 
The researchers estimated that this would be net cost saving to the degree of 163,700-
445,800 total dollars per 1000 people from decreased cancer expenditures that are greater 
than costs of screening, surveillance, and complications.85 
Lack of evidence for benefits, risks, and epidemiologic shift 
Experts in the field have argued that there is a lack of empirical evidence for 
changing guidelines when considering the weighing of benefits, risks, and costs 
associated with such a change. This is evidenced by the American Cancer Society’s own 
designation of these recommendations as qualified, rather than strong.3 Much of this 
concern stems from the lack of empirical data and evidence for screening in individuals 
under the age of 50 due to the long standing consensus on recommendations to initiate 
screening starting at age 50.3 Because of this, the ACS reliance on modeling studies to 
guide their recommendation has come under scrutiny and calls for more research to 
collect direct evidence in this area to be released.15 Some authors have speculated 
whether the upwards trends in incidence, while mortality remains steady, may be due to 
increase in screening utilization detecting more polyps (lead-time bias) rather than an 
actual increase in disease burden.86 However, authors such as Siegel, et al. argue that the 
most steep incidence trends are found in the youngest age groups or those that are least 
likely to be getting colonoscopies.8  
Shifting Guidelines and Insurance Coverage 
Insurance coverage for preventive services such as screening for colorectal cancer 
is mandated for non-grandfathered private health plans87 by the Patient Protection and 
Affordable Care Act (ACA) (2010).88,89 The ACA requires Medicare and private 
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insurance to cover these services with no out-of-pocket costs. The ACA stipulates that 
only services given an A (high) or B (moderate) rating by the USPSTF are covered by 
this provision, however, this does not exclude individual insurance companies from 
deciding to cover CRC screening.88 Because the USPSTF has kept its current 
recommendation at 50, rather than 45, individuals under 50 who seek screening may be 
subject to the costs associated with this service. The previous 2016 recommendation from 
the USPSTF, released prior to the updated ACS recommendation, concluded that the 
evidence supports screening beginning at age 50 because of the uncertainty around 
benefits and risks of screening in younger people. This statement also references the 
increasing risk in younger individuals as a current research gap.  The USPSTF is 
currently acting in the ‘review the evidence and develop a draft recommendation’ stage 
of updating their guidelines for colorectal cancer screening. 90 Shedding light on issues 
surrounding screening in younger people, such as the ones addressed in this study, could 
provide more certainty around the potential benefits and risks and bolster evidence for the 
USPSTF and other policy organizations to also shift their recommendations. Shifts in 
these guidelines will eventually lead to shifts in insurance coverage and thus changes in 
practice.  
Other considerations   
Other unintended consequences that are noted in the literature are important to 
consider when substantially shifting guidelines for CRC screening. Liang et al. explained 
that, as previously mentioned, resources to promote and deliver screening for the people 
at highest risk may be diverted to lower risk populations rather than where they are 
needed the most. 13 These authors also argue that lowering the recommended age for 
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screening could increase disparities in CRC because people of higher socioeconomic 
status, who have more money and knowledge, are more likely to benefit from innovation 
and new health interventions. 13 
While there is much controversy surrounding the new ACS recommendation, this 
shift in thinking has opened doors for new lines of inquiry related to screening for 
colorectal cancer in younger individuals. This literature remains sparse because most 
studies focus on people within the window of recommended screening. The following 
sections will summarize the existing literature as it relates to the corresponding research 
questions that I will explore.  
2.8 Evidence for the Association Between Age and Colorectal Cancer Screening 
Disparities/Outcomes 
The necessity to explore research questions related to younger age and colorectal 
cancer screening extends beyond the epidemiologic shift towards higher risk in younger 
individuals. ACS recommendations for individuals under 50 are qualified and other 
professional organizations have been hesitant to endorse screening in younger 
populations because of the lack of direct evidence for the benefits and risks. In our 
research program, we have consistently identified younger age as a predictor of screening 
variables. Findings from these studies add credence to the research questions and 
hypothesis explored in this dissertation project because, if these outcomes are a consistent 
trend, additional considerations for this group must be factored into screening programs.  
Briefly, in a sample of 1492 pre-colonoscopy patients and their caregivers, 
younger individuals reported experiencing more social and practical problems when 
attaining colonoscopy.91 Problems that younger individuals identified more often than 
older included difficulty finding time off work, difficulty in finding a driver who is able 
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to take time off of work, costs associated with the procedure, and finding care for 
children or elders. Younger patients were also more likely to experience financial strain 
when attaining colonoscopy as well as having sought colonoscopy because they were 
symptomatic. 92 Younger patients were more likely to experience poor colonoscopy 
preparation than their older, screening-aged, counterparts. In recent work by Mueller and 
colleagues, 96% of the sample age 25-46 were able to identify colonoscopy as a CRC 
screening tool, however, < 60% identified FOBT, <40% identified stool DNA, and only 
20% identified sigmoidoscopy as tools used to screen for CRC. In the same sample, over 
half of participants were not able to identify that risk for CRC was increasing in people 
under the age of 50.24 
2.9 Shared Decision-making and Colorectal Cancer 
 
The shared decision-making framework is appropriate given the evidence of the 
rising CRC rates, the shifting landscape of CRC recommendations, and the uncertainty 
about the benefits versus the costs and risks. There are at least 2 decisions that patients 
and their doctors must make: whether to initiate screening and which screening strategy 
to complete.23 These decisions can be complex due to the uncertainty about risks and 
benefits in this age group and the numerous testing options that exist that each have 
unique features, schedules, advantages, and disadvantages. 
There is evidence in the literature that shared decision-making leads to higher 
intention to be screened and higher satisfaction with the decision-making process,93 
however, evidence for individuals getting their preferred test is inconsistent.94,95 
Moreover, in some clinical sites, shared decision-making procedures in the context of 
colorectal cancer screening may not be conducted at all. Wunderlich et al. found that 
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while 70% of their patient sample seeking screening preferred shared decision-making, 
only 47% reported that their decision for screening was shared with their physician, and 
only 1/363 primary care visits contained all four elements of shared decision-making that 
the authors were assessing.96 Ling and colleagues (2008) found that over 50% of clinical 
interactions that they studied did not include any of 9 elements of shared decision-making 
conversations that they were assessing97 In some scenarios, such as when a patient is 
symptomatic, a shared decision may not be appropriate, because diagnostic colonoscopy 
is the most appropriate decision.  Studies containing samples under age 50 are sparse so a 
number of questions about shared decision initiation, process, and outcomes remain 
unanswered in the literature. 23 In this dissertation, I addressed three research questions 
related to shared decision-making for colorectal cancer screening in individuals under 50. 
These questions descriptively explore antecedents to making a shared decision in 
individual under age 50. This study will also test differences between individuals who 
have not been screened <50 age group and the 50+ age group to examine important 
differences that must be considered when building screening programs that incorporate 
younger people.  
2.10 Remaining Questions: Literature review and rationale for research questions 
 
RQ1: Are people under age 50 able to correctly identify risk factors of CRC? 
Research exploring colorectal cancer in younger individuals points to a higher risk for 
younger patients to present with later stage CRC than their older counterparts. 98,99 For 
example, in a study conducted in 2016 using a large sample drawn from the SEER 
database, a multinomial logistic regression controlling for sex, race, marital status, tumor 
location, and year of diagnosis, indicated that younger patients (<50) compared to older 
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patients (>50) had a 1.37 relative risk ratio (RRR) for developing regional (Stage III) 
disease when compared to local disease (Stage I or II), and a 1.58 RRR for distant disease 
(Stage IV) than localized disease.  
Reasons for this phenomenon are explained in several ways in the published 
literature. First, it is likely that many of these cancers are not caught by the routine, 
guideline-based screening that is generally recommended for individuals over the age of 
50. Second, patients and their doctors may misattribute symptoms or ascribe less severity 
to these symptoms in younger individuals, thus increasing time to workup and diagnosis. 
In 2015, Dozois, et al. found that the majority of patients under the age of 50 (mean 
age=42) at their institution presented with late stage disease (Stage III or IV) and were 
symptomatic at the time of diagnosis.100 Symptoms seen in this population were most 
commonly rectal bleeding (51%), abdominal pain (32%), change in bowel habits (18%), 
and weight loss (13%). Chen and colleagues (2018) found that the median time to CRC 
diagnosis in their setting for people under the age of 50 was 128 days versus 79 days for 
those over 50 and the mean time to diagnosis was 152 days versus 87.101 Multivariable 
analysis support these findings, time to diagnosis in those under 50 was 1.4 times longer 
than their older counterparts. While at a population level, the clinical relevance of a 60 
day differential in time to diagnosis is not certain, the differential may be driven by a 
select number of individuals whose symptoms were misattributed, and thus, those at the 
extreme of the time to diagnosis range may suffer the most from any delays in diagnosis. 
In the above sample, this is evidenced by the maximum time to diagnosis for both age 
groups. For the under 50 age group the maximum time to diagnosis was 265 days while 
for the older group the maximum was only 184 days.  Third, Younger people may 
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encounter more challenges that delay screening or diagnostic procedures when navigating 
the CRC screening system.91 These challenges could present as social problems such as 
difficulty finding somebody to come to the appointment or practical such as arranging 
childcare or paying for procedure. Finally, key biological differences may exist between 
cancers that are occurring in younger individuals than those found in older 
populations.101,102 
Risk factor identification. 
The ability to identify risk factors associated with CRC would be a valuable tool 
for initiating screening at an age under what is generally recommended for screening. If a 
patient has one or more risk factors, this may influence their decision to seek or proceed 
with screening. Further, the patient having adequate knowledge of the decision at hand 
and the ability to assess that knowledge are important components in shared decision-
making. 18 However, the recent dissertation work by Mueller et al.24 indicates that 
younger individuals’ knowledge of increasing risk and screening tests is low. This is 
consistent with the hypothesis that CRC is likely not on younger people’s ‘radar’.103 It 
follows that younger people may also have less knowledge of important and potentially 
compounding risk factors  
A number of studies have been conducted that explore CRC risk factor 
identification in the United Kingdom104,105, Ireland106, Hong-Kong107, Kuwait108, and 
Bahrain;109 however, little published work on this subject in the United States could be 
identified and none of these studies focused specifically on younger people. However, a 
2019 Master’s thesis, published online, provided additional evidence for age effects in 
CRC knowledge. The author found that higher knowledge of risk factors was 
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significantly associated with being less than 27 years old compared to over 27 in a 
sample of individuals age 20 to 40. This study did not explore this relationship in a 
multivariable model.110 Additionally, this study was limited in its external validity as it 
recruited only employed millennials between age 20 to 40. 
In the United Kingdom, Power et al. sought to create and validate a scale called 
the Cancer Awareness Measure for Colorectal Cancer to assess people’s ability to 
identify both risk factors and symptoms of bowel disease.104 This ‘scale’ utilized both 
unprompted qualitative responses as well as a prompted checklist to assess knowledge of 
risk factors. This study found that knowledge of risk factors was low in this population 
and multivariable analysis indicated that higher social status and white race were related 
to higher knowledge, however, other ethnicities scored higher for identifying risk factors 
such as eating processed meats and low physical activity.   
There is a distinct gap in the literature around younger people’s knowledge of risk 
factors for CRC, especially in the United States. Additionally, these gaps in knowledge 
may be related to demographic and literacy/activation variables that could be leveraged 
when creating, tailoring, and targeting educational interventions.   
RQ2: What screening strategy do individuals under 50 prefer and on what are these 
preferences based?   
Patient Preferences for Screening Tests  
The second remaining question relates to people’s preferences for testing, which 
is an essential component of the shared decision-making process. In fact, a 2010 NIH 
state-of-the-science conference statement included patient preferences as a key question 
to be answered and a priority for research stating:  
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“The effect of patient preferences on colorectal cancer screening rates has 
not been well studied. We know very little about how preferences for 
screening modalities are formed; how they are related to knowledge, 
beliefs, and cultural norms; and whether these preferences vary across 
sociodemographic groups. It is also unknown whether patient preferences 
change [or] vary over time; it is also unknown what factors may influence 
that change. Given the multiple options for colorectal cancer screening, 
interventions that provide decision support and incorporate patient 
preferences may be effective at increasing colorectal cancer screening rates 
across diverse populations.” 111 
While some research has explored preferences (summarized below), the 2018 
ACS recommendation statement notes that consistent evidence for patient preferences for 
screening strategies has not yet been established and very little evidence exists for 
individuals under the age of 50. While people generally prefer one strategy over another 
when given a choice, we know little about what the features of tests are that lead to these 
preferences in individuals under age 50.  
Descriptive preferences and predictors of strategy preference   
Several studies have descriptively explored patient preferences for tests that 
screen for CRC. A systematic review of preferences in vulnerable populations including 
racial and ethnic minorities, veterans, rural and low income individuals shows large 
variability in preferences for screening modality and strategy attributes.112 The authors of 
this review found 43 articles that explored patient preferences for screening that 
contained samples with a high proportion of vulnerable individuals in their sample. The 
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authors also highlighted the small number of studies that explored how preferences are 
formed around strategy attributes. A sample of the studies that represents the lack of 
consensus on this topic is summarized below:  
In 2014, Ruffin and colleagues explored this question by conducting 10 focus 
groups and surveying 93 previously unscreened participants between ages 50 and 70 
(mean 60). 113 Participants in focus groups were presented basic information (purpose, 
process, preparation, pain, test accuracy, frequency, and follow up testing) about 
colonoscopy, FOBT, double contrast barium enema, and flexible sigmoidoscopy. In this 
sample, 49% of participants preferred colonoscopy, 39% of participants preferred 
FOBT, 7% preferred barium enema, and 5% preferred flexible sigmoidoscopy. 
Participants identified thoroughness and accuracy of information provided, not needing 
follow up testing for 10 years, and relative painlessness because of anesthesia as reasons 
for colonoscopy preference. Reasons for FOBT preference were identified as simplicity, 
convenience, privacy, and the annual testing interval. No statistically significant 
differences were found for demographic subgroups but, descriptively, more Caucasians 
than African Americans preferred FOBT (46% vs 30%) and more African Americans 
preferred colonoscopy (55% vs 44%). 
 A 2011 3-arm randomized control trial of a computer-based decision aid for CRC 
screening explored this question in 666 primary care patients age 50 to 75 (mean 57) who 
had never been screened.93 In both intervention arms, the majority (59%) of patients 
preferred colonoscopy, 26% preferred FOBT and a small minority of patients 
preferred the other screening modalities. Patients who selected colonoscopy as their 
primary choice identified accuracy as the most important test feature. In those that chose 
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FOBT, inconvenience, discomfort, and bowel preparation were the most noted concerns. 
When the authors tested demographic features including age, sex, race/ethnicity, 
education, and insurance status, no significant associations were found for preference of 
FOBT or colonoscopy.  
Only one study in the literature explicitly assessed preferences in individuals in 
the 40 to 49 age group114 (besides one that included individuals 49+115). This study, 
conducted in 2008, recruited 323 previously unscreened (with colonoscopy) supermarket 
participants, of whom, the majority (63%) were below the age of recommended screening 
(age 40 to 49).114 When presented with side by side information about FOBT and 
colonoscopy “nature”, “safety”, “frequency”, “convenience”, “accuracy”, “cost”, and 
“follow-up testing”, 53% preferred FOBT and 47% preferred colonoscopy. 
Demographic features associated with FOBT preference included Latino ethnicity 
(compared to non-Latino whites), and lower education.  Family history of CRC and 
previous experience with sigmoidoscopy were associated with preference for 
colonoscopy. While age was not significantly associated with test preference, 44.9% of 
people in the under 50 age group preferred colonoscopy while 49% and 63.6% in the 50 
to 64 and 65 to 79 age groups, respectively, preferred colonoscopy. This study may have 
been underpowered to detect these differences because the sample was primarily under 
the age of 50. Like other studies, test accuracy and convenience were noted as the most 
important reasons for preferences for colonoscopy and FOBT, respectively.  
Decision Models  
Some work has explored these preferences using the Analytic Hierarchy Process 
(AHP) (Table 2). This method focuses on exploring criteria that people prioritize when 
making decisions involving multiple options with differing features (see Chapter 4 for 
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details). In adults age 50 to 85, Dolan, et al. found that patients recruited from primary 
care practices weighted the most important criteria for assigning priorities as preventing 
cancer (mean priority score 54%), avoiding side effects (18%), minimizing false positives 
(15%), and logistics (12%) when comparing these criteria among 10 CRC screening 
modalities.116 
 A study by Xu and colleagues117 performed a similar decision-making study in a 
unique sample of patients age 40 to 75. These individuals were already scheduled for 
screening or surveillance colonoscopy. Recruitment included sending FIT kits with 
recruitment materials and data-collection surveys were completed the following day after 
their completed colonoscopy. In this sample, results indicated that patients who had 
completed both tests slightly preferred FIT over colonoscopy with aggregated 
priority scores of .517 and .483 respectively. The rank for importance of criteria 
identified by this study were test accuracy (45.7%), complications (32.1%), and finally 
test preparation (22.3%). While this study’s inclusion criteria included individuals age 
40+, the average age of the analytic sample was 56.7 and no subgroup analysis was 
presented for participants under the age of 50.  
Finally, a Dutch AHP study conducted by Hummel et al. in individuals 55 to 75 
found that preference weights were .26 for sensitivity, .26 for safety, .24 for specificity, 
.15 for frequency, and .09 for convenience choosing between FIT, colonoscopy, 
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Preferences for screening tests are inconsistent in the literature, and very little is 
known about preferences for people who generally fall outside of the range for initiation 
of age-based screening. Additional work must be conducted in this age group to 
determine what the preferences for CRC screening are, what these preferences are based 
on, and whether these preferences are related to any key sociodemographic features that 
providers could leverage to help patients make informed decisions about screening. This 
information can be utilized to create and enhance existing decision-making tools used in 





RQ3: When making CRC screening decisions, what level of control (role preference) 
do people under 50 prefer and do they feel confident in their ability to make 
decisions? 
Patient willingness to participate in shared decision-making is a critical 
component of the process.19,119 However, there may be considerable variation in an 
individual’s desired role.25 It follows that if a patient prefers a shared or patient driven 
role in decision-making, their self-efficacy for making that decision must also be high. A 
seminal review on shared decision-making by Fosch and Kaplan indicated that 
willingness to participate in shared decision-making ranged from 19% to 63% depending 
on the sample and health concern being studied.25 They also found that younger and more 
highly educated individuals tended to desire more involvement in making medical 
decisions. A 2012 systematic review of 115 studies on shared decision-making 
preferences in patients found that, in 63% of studies assessed, shared decision-making 
was the majority preference while, in 21% of studies, physician delegated decision-
making was preferred by the majority of participants.120 The authors of this study found 
variation in desire for shared decision-making between samples that were drawn from 
cancer decision- (77% preferred SDM) and general population- studies (53%) indicating 
that role preference could be contextual. 
For colorectal cancer screening there is not as strong a consensus on when to 
initiate screening and no screening method is recommended consistently above others. In 
this instance, people may be more likely to want to defer the screening decision to their 
physician, or alternatively, they may want more involvement when uncertainty is 
involved. This issue is complicated because patients may be unaware of or confused by 
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current guidelines,121 especially when long-standing guidelines become part of patients’ 
general knowledge through public health and media messaging (i.e. ‘get your 
colonoscopy at age 50’), and when physicians have reservations or disagree with new 
guidelines.122  
Measuring patient’s desired role in colorectal cancer screening decisions  
Previous work on a primarily African- American, female sample of primary care 
patients (mean age 56.4) indicated that approximately 10% of their sample preferred 
physician based decision-making while 48% preferred patient based and 41% preferred 
shared decision-making.93 In another sample, consisting of primarily white individuals, 
45% preferred decision-making to be shared with the doctor, 25% desired to be the 
primary decision maker (after considering the doctor’s opinion), 16% preferred the doctor 
to make the decision, and 15% preferred to make the decision on their own. 94  Several 
demographic features were associated with preferences in this sample including black 
race preferring shared decision-making and lower education preferring doctors to make 
the decision. Finally, in a primarily Hispanic sample, a collaborative role was preferred 
by 53.3% of participants while passive was preferred by 26.4%.123 However, none of 
these studies included individuals who were under the age of 50, so very little 
information is available in the literature regarding these individuals’ preferences for 
participating in the colorectal cancer screening decision-making process. Unanswered 
questions remain about individuals in younger age groups desired role in decision-
making about colorectal cancer and whether they have confidence in their ability to 
perform this role. On the one hand, younger age may play a role in increased desire to be 
more engaged, while on the other, uncertainty and lack of clarity on guidelines and 
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screening modalities may influence these people to defer decisions to their doctors. If 
younger patients want patient driven or shared decision-making for CRC screening, they 
must also have the self-efficacy necessary to carry out those decisions. If decisional self-
efficacy and desired role are mismatched, tools can be built to increase self-efficacy for 
making decisions, thus, empowering patients and improving satisfaction with the process 
and adherence to screening plans. 
Conclusions: 
With shifting guidelines about when to initiate screening for colorectal cancer, 
new doors for scientific inquiry have opened. Almost no work in the colorectal cancer 
literature has included samples of individuals who are under the age of 50 due to the 
long-standing guidelines that recommend initiating age-based screening at 50. While only 
the American Cancer Society has currently recommended shifting the age to 45, there is 
growing evidence for increasing risk in younger individuals. As evidence accumulates, 
other policy recommending entities may follow suit and begin advising people under 50 
to be screened. When guidelines change, especially those issued by the USPSTF, 
insurance coverage for the tests will shift and so will practice. However, varying 
protocols, uncertainty and lack of consensus make using a shared decision-making 
framework appropriate for individuals under the age of 50. The aims of this project will 
fill gaps in the current literature by exploring several components of the shared decision-
making process. Within these areas, there is a distinct lack of literature that can be used to 
build tools to guide clinicians and their patients when navigating these decisions.  In this 
dissertation I explored 3 key questions about: (1) knowledge of CRC risk factors; (2) 
preferences for screening tests; and (3) desire and self-efficacy to engage in decision-
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making in this context. This study is innovative because most previous work on this topic 
has included individuals within the previously agreed upon guidelines for appropriate 
initiation of screening and has not included individuals below age 50. However, 19 
million people may now be in the age group that would benefit from screening. 
Answering these questions will be essential for improving clinical interactions, ensuring 
screening when appropriate, and continuing to reduce CRC incidence and mortality.  
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Chapter 3: Is Colorectal Cancer on their Radar?  Symptom and Risk 
Factor Identification and the Moderating Role of Age 
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Introduction: Colorectal cancer is an essential cancer control priority and improvements 
in uptake of screening have reduced mortality from the disease. However, in individuals 
under 50, the incidence of colorectal cancer is increasing and cancers in this population 
are often found at a later stage. In order for younger people to make informed decisions 
about colorectal cancer, they must be knowledgeable about the disease. Little work has 
been conducted in the United States evaluating younger people’s knowledge of risk 
factors and symptoms of colorectal cancer.  In this study, we investigate individuals 
under age 50 and their knowledge of colorectal cancer, predictors of symptom and risk 
factor knowledge and the moderating role of age on these associations.    Methods: We 
recruited 579 participants from Amazon Mechanical Turk (MTurk) for a survey on 
perceptions about colorectal cancer screening. We assessed risk factor knowledge by 
creating an index of 8 true risk factors and 2 false risk factors and we assessed symptoms 
using 5 ‘true’ symptoms and 3 ‘false’ symptoms. Scores on each index were scored and 
analyzed separately and in aggregate. We used linear regression models to evaluate 
demographic and cancer experience variables as predictors of total index scores. We split 
the sample into two groups (<50 years old and ≥50) to test the moderating role of age. 
Results: Knowledge of both symptoms and risk factors was adequate and did not differ 
by age group. However, we found evidence for the moderating role of age. In the <50 age 
group, subjective numeracy (p=.008), knowing somebody close who was tested for CRC 
(p=.006), and commitment to testing (p=.048) were significant predictors of risk factor 
knowledge. For symptoms, female gender (p=.039), knowing somebody close who was 
tested(p<.000), and perceived likelihood of getting cancer (p=.033) were moderated by 
age. Discussion: Results of this study indicate that age will be an important factor to 
consider for future research. As risk continues to rise in younger populations, we must 
address knowledge of the disease to ensure that younger people are able to make 
informed decisions about their healthcare. 
Colorectal Cancer in younger people 
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The overall burden of colorectal cancer (CRC) is declining in the United States, 
however, it still represents the third highest mortality of cancer sites for both sexes.2,8,26 
Population-based analyses also indicate increasing rates of CRC among individuals under 
age 50.72 Currently, 11-12% of colorectal cancers are identified in people under age 50 
and yearly increases in incidence for people under 50 range from approximately 1.3-2.4% 
in colon cancer and 2.3-3.2% for rectal cancer.8,72 Steep increases in incidence when data 
are analyzed year-by-year also show that many cancers in people age 45-49 remain 
undetected until they initiate screening at age 50.124 In response to this epidemiologic 
shift and an evaluation of benefits versus burdens, the American Cancer Society 
reevaluated their recommendation to initiate screening in average risk individuals at age 
50.3 In the updated guideline statement, they gave a qualified recommendation for people 
age 45-49 to consider initiating screening. If the lowered screening age were widely 
adopted by the United States Preventive Services Task Force (USPSTF), approximately 
19 million individuals would be added to the eligible screening should they seek 
screening.88,89,125 Despite this increasing risk and potentially changing guidelines on 
when to initiate screening, colorectal cancer may not be on younger people’s ‘radar’.103 
This could be due, in part, to younger people’s thoughts of cancer as a disease that older 
people get and the consistent messaging that CRC, in particular, is not something to think 
about until they turn fifty.8,103  
Risk factor and Symptom identification  
An individual’s ability to identify risk factors associated with CRC could 
influence their decision to initiate screening at a younger age than recommended. Young-
onset CRC patients are also at higher risk of presenting with later stage CRC than their 
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older counterparts and may be symptomatic at the time of diagnosis. 98,99  Reasons for 
worse clinical manifestation are likely part biological100,102 but could be associated with 
doctor and patient misattributing or ascribing less severity to symptoms of possible 
cancer. In 2015, Dozois, et al. found that the majority of patients under the age of 50 
(mean age =42) at their institution presented with late stage disease (Stage III or IV) and 
were symptomatic at the time of diagnosis.100 Symptoms seen in this population were 
most commonly rectal bleeding (51%), abdominal pain (32%), change in bowel habits 
(18%), and weight loss (13%). When symptoms do arise, younger patients may also 
encounter different challenges than older individuals when navigating the colonoscopy 
procedure used for diagnosis.91 For example, younger people experience more social and 
practical problems like difficulty finding somebody to come to the appointment, 
arranging childcare or paying for procedure. These factors can increase time for a patient 
to visit a provider, increase work-up time, lead providers down an incorrect treatment 
path, or otherwise increase the amount of time from symptom onset to diagnosis.100,101 
Knowledge of CRC symptoms could empower individuals to seek care and advocate for 
more testing, especially when multiple factors are present.  
A number of studies have been conducted that explore CRC risk factor and 
symptom identification with varying results104–109. Knowledge of risk factors and 
symptoms vary by demographic features of participants. For example, in a representative 
sample conducted in Great Britain, awareness of risk factors was independently 
associated with white ethnicity and higher socioeconomic group while awareness of 
symptoms was associated with being female, white ethnicity, higher socioeconomic 
group, and familiarity with cancer.104   However, little work has been published in the 
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United States and these studies have not focused specifically on the moderating role of 
age for an individual’s ability to identify risk factors and symptoms of CRC.  
As our knowledge of increasing CRC risk in younger people grows, it is prudent 
to build on the existing literature around younger individuals’ understanding of CRC risk 
factors and symptoms. However, the overwhelming body of literature on colorectal 
cancer has focused on people over 50.  This has left a distinct gap in our understanding 
about how younger people perceive CRC and their knowledge about the risk factors for 
the disease. Recent work supports that younger people are confused about the types of 
CRC screening tests available and they may be unaware of their  increased risk of 
developing the disease.24 Given the uncertainty surrounding screening for colorectal 
cancer, the rising risk in younger people, and the relative equality in effectiveness of 
screening options, CRC related screening and diagnosis decisions should also consider a 
shared decision-making framework. A shared decision-making framework stipulates that 
an individual is knowledgeable about the disease, their individual risk, and the different 
options available to them so that they can make an informed choice.19 As a next step, we 
aim to classify differences around risk factor and symptom awareness for colorectal 
cancer by age groups. Additionally, we explore how gaps in knowledge related to 
demographic, cancer experience, and psychological variables are moderated by age. This 
information can be leveraged when creating, tailoring, and targeting educational 
interventions for younger people, when considering how to best incorporate younger 
people into screening programs, or, when developing research agendas to fill gaps in 




This study was part of a larger study on perceptions about colorectal cancer in 
individuals under age 50. Survey data were collected using Qualtrics126 after participants 
self-selected to participate from Amazon Mechanical Turk (mTurk). MTurk describes 
itself as a crowdsourcing global workforce for individuals that complete a variety of 
tasks, including research tasks.127 MTurk workers (Turkers) represent diverse individuals 
from across the globe and previous work with Turkers has shown that they produce high 
quality research data, even when presented with complex behavioral tasks that are 
traditionally conducted in-person.128 We took best- practice measures to ensure high 
quality data including requiring workers to have completed tasks with a high approval 
rating and including qualitative responses to screen for ‘bots’ or automated responses. 
Initial inclusion criteria related to participant characteristics for this study included being 
ages 45-55, living in the United States, and never having been screened for colorectal 
cancer. After initial collection of 482 participants, we then released the survey to all 
individuals over 18 who met these criteria.  
Knowledge Index of CRC Risk Factors: 
We assessed risk factor knowledge by creating an index of 8 true risk factors and 
2 false risk factors. Eight true risk factors were: increased age3; higher body mass index 
(BMI) (obesity)129; smoking cigarettes or using other tobacco products130; heavy alcohol 
consumption131; a family member with colon or rectal cancer132; inflammatory bowel 
disease such as irritable bowel disorder (IBD), Crohn’s disease, or ulcerative colitis133; 
diabetes,134 and diet high in red meat or processed meat.135 False risk factors included 
exposure to violent video games and exposure to the sun without sunscreen. Each 
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question was phrased: “Which of the following would increase the risk for somebody to 
get colon or rectal cancer?” Participants were given the option to respond “yes”, “no” or 
“I don’t know”. Scores for the index were calculated as a sum of correctly identified 
(“yes”) true risk factors (range: 0-8). ‘I don’t know’ was not considered to be a correct 
response for true risk factors. False risk factors were also assessed using ‘yes’ responses 
for false risk factors (range 0-2). For analysis, false risk factors were dichotomized to 
0=no false risk factors identified, 1= 1 or more false risk factors identified. 
Knowledge Index of CRC Symptoms: 
Symptoms were assessed in a similar manner using 5 ‘true’ symptoms and 3 
‘false’ symptoms. Questions were phrased “which of the following are likely symptoms 
of colon or rectal cancer?” and response options included “yes”, “no”, and “I don’t 
know”. True symptoms included: blood when you wipe after using the bathroom; 
persistent abdominal pain; anemia (paleness, weakness, fatigue); unexplained weight 
loss; and change in bowel habits. False symptoms were indigestion or heartburn; 
persistent headaches, the urge to urinate often. Scores for correctly identified true 
symptoms (range 0-5) and identified false symptoms (range 0-3) were also calculated 
using “yes” responses. For analysis, we collapsed false symptoms into 0= no false 
symptoms identified, 1= 1 false symptom identified, 2= 2 or more false symptom 
identified. 
Independent Variables 
Demographic variables included age (1= <50, 2= ≥50); education (1= High school 
or less, 2= some college, 3= college completion, 4=higher than college); household 
income (1= <30k, 2=30-59,999, 3=60-89,999, 4= >90k); gender identity (1=man, 
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2=woman), self-identified primary race (recoded as 1=white, 2=other); type of insurance 
coverage (recoded as 0=no, 1=public, 2=private for regression and 0=no, 1= yes for false 
risk factor analysis), relationship status (recoded as 1=single, 2=dating or cohabitating 
but not married, 3=married). We also assessed general health (continuous 1=Poor, 
5=excellent); health literacy136 (continuous 4-20); subjective numeracy137 (continuous 1-
6); confidence in seeking advice on medical topics (continuous 1= not confident at all, 
5=completely confident); and having a regular medical provider (0=no, 1=yes) as 
independent variables. Finally, we included independent variables related to cancer 
experience: having somebody close who has died of cancer (0=no, 1=yes); family, 
spouse, or anybody else close having been tested for CRC (recoded 0=no/don’t know, 
1=yes); self being diagnosed with cancer (0=no, 1=yes); worry about cancer (continuous 
1=not at all, 5=extremely); perceived likelihood of getting cancer (1= very unlikely, 5= 
very likely); and stage of commitment to CRC testing (1=have not thought about getting 
tested-5=committed to getting tested) .  
Analysis:  
We calculated descriptive statistics for demographics, individual symptom and 
index items, and overall index scores. We also used ANOVA to determine differences in 
the mean index scores of the two age groups (<50, ≥50). We used multivariable linear 
regression models to test independent predictors of total index scores in the full sample 
and in each age group.  To contextualize the associations found in linear regression 
models, we also performed ANOVA and χ2 tests to determine if significant variables 
were also associated with higher false symptom and risk factor scores in the overall 
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sample in age subgroups. We calculated 2 sided Fishers exact statistics for categorical 
variables when cell sizes were less than 5. All analyses were conducted using SPSS v26. 
Results: 
Sample demographics 
The demographic features of the sample can be found in Table 1. The sample was 
majority women, white/Caucasian, English speaking, born in the United States, and 
married. Approximately 54.9% of the sample had completed a college degree or above 
and most participants were insured with either private (67.9%) or public insurance 
(15.5%).  
Individual and combined knowledge scores 
Knowledge of individual risk factors and symptoms can be found in Table 2. 
Participants’ ability to identify risk factors ranged from 44.2% for diabetes to 88.9% for 
family history of CRC. On average, participants scored 5.5/8 on the risk factor index 
(range 0-8). About 9.1% of the sample identified 1 or more false risk factors as a true risk 
factor. Participants’ ability to identify symptoms varied from 59.8% correctly identifying 
persistent anemia to 85.8% correctly identifying blood when you wipe after using the 
bathroom. The average score for symptom identification was 3.7/5 (range: 0-5). A 
number of participants (38.3%) identified one or more of the false symptoms. For both 
true risk factors and true symptoms, participants were much more likely to respond ‘I 
don’t know’ rather than correctly identifying a false symptoms and risk factors as such. 
ANOVA results indicated that participants <50 and 50 and older scored similarly 
on both the symptom and risk factor index. Mean symptom scores for the <50 age group 
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were 3.6 and 3.8 for ≥ 50 (F=1.808, p=.179). For risk factors, the mean scores were 5.6 
(<50) and 5.5 (≥50) (F=.361, p=.548).  
Multivariable linear regression Risk factors: 
Regression results for risk factors can be found in Table 3. In the full sample, 
higher scores on the risk factor index were associated with higher levels of cancer worry 
(B=.182, p=.035) and perceived likelihood of getting cancer (B=.207, p=.05); public 
insurance vs private (B=.586, p=.031); having a family member, spouse, or other 
anybody else close who has been screened for CRC (B=.601, p=.001);  higher subjective 
numeracy (B=.284, p=.003), and higher commitment to getting tested for CRC (B=.160, 
p=.016). In the subgroup analysis, for individuals under age 50, higher subjective 
numeracy (B=.336, p=.008); family, spouse, or anybody else close screened for CRC 
(B=.639, p=.006); and commitment to getting tested (B=.167, p=.048) remained 
significantly associated with higher risk factor index scores. In those over 50, having 
been previously diagnosed with cancer emerged as predictive of lower index scores (B=  
-.921, p=.044) and public vs private insurance remained significantly associated with 
higher index scores (B=1.243, p=.007). None of the variables that were significant in the 
full models or age subgroup models were associated with false risk factor identification at 
the bivariate level. 
Multivariable linear regression Symptoms: 
Results of the multivariable linear regression results for symptom index scores 
can be found in table 4. Results for the full sample show significant associations between 
higher symptom knowledge and female gender identity (B=.354, p=.007); having 
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somebody close that has died of cancer (B=.301, p=.022); and family, spouse, or anybody 
else close that has been tested for CRC (B=.397, p=.003). In the under 50 age group, 
associations remained for female gender identity (B=.348, p=.039) and family, spouse, or 
anybody else close tested for CRC (B=.608, p <.000) and perceived likelihood of getting 
cancer (B=.216, p=.033). In the ≥50 age group, only having somebody close that has died 
from cancer remained associated with higher symptom knowledge scores (B=.648, 
p=.003). None of the significant variables in the full model or age subgroup models were 
significantly associated with false symptom identification at the bivariate level. However, 
the association between higher false symptom scores and perceived likelihood of getting 
cancer approached significance for the ≥50 age group (mean range: 3.07-3.47, F=2.93, 
p=.055). 
Discussion: 
Participants’ ability to identify risk factors was generally high (range: 44.2%-
88.9%). However, lower levels of knowledge pertaining to modifiable risk factors such a 
tobacco use (47%), and heavy alcohol consumption (52.8%) are important to note as 
these behaviors are related to multiple cancers and other health conditions. Participants’ 
ability to identify individual symptoms was also high (range: 59.8%-85.8%) but 
identification of the symptoms that are related to general cancer (persistent anemia and 
unexplained weight loss) were lower than symptoms specific to colorectal cancer (blood 
in stool, abdominal pain, and changes in bowel habits). This could be explained by 
participants using context clues about gastrointestinal symptoms, rather than actual 
knowledge about the symptom’s association with colorectal cancer. Consistent with this, 
Power and colleagues (2011) explored knowledge using unprompted assessments and 
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found that their sample had very low knowledge of symptoms when not provided a list of 
possibilities.104 When prompted, participants in their sample had much higher knowledge 
of symptoms, similar to this study. The distinction between prompted and unprompted 
responses is important when considering the measurement of knowledge in community 
samples and a multi-step approach could more accurately classify an individual’s 
baseline knowledge about both symptoms and risk factors. Furthermore, providing 
information about risk factors and symptoms specific to CRC and generally to cancer 
should be considered when designing interventions to improve knowledge. 
In this sample, participants in both age groups had similar knowledge about risk 
factors and symptoms of colorectal cancer. While we did not find differences in the 
overall scores for each index between age groups, we did find that the overall scores were 
associated with different participant characteristics. This is evidence that an individual’s 
age moderates these relationships. For younger people, having a family member, spouse, 
or anybody else close who has been tested for CRC was predictive of higher scores on 
both the risk factor and symptom index. Personal experience with colorectal cancer 
screening is likely important when considering the best way to improve knowledge about 
the disease. Individuals with higher baseline experience with colorectal cancer testing 
might benefit less from interventions that aim to increase knowledge of CRC risk factors 
and symptoms. Unique to the under 50 age group, male gender was associated with lower 
knowledge scores on symptom identification and those with lower numeracy scored 
lower on risk factor identification. Additionally, individuals under 50 that were less 
committed to getting tested for CRC were more likely to have lower risk factor 
identification scores. These features warrant further study and can be used to identify 
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younger people who are at higher risk of having lower knowledge and thus benefit from 
educational interventions or targeted public health messaging.  
We found that perceived likelihood of getting cancer and cancer worry were 
associated with higher risk factor index scores in the overall sample. It is possible that 
those who worry more about cancer or perceive their likelihood of getting cancer as 
higher are more likely to identify more risk factors, regardless of whether they are ‘true’ 
or not. However, we did not find evidence that participants in the overall group and in 
each age subgroup were erroneously identifying all of the presented risk factors and 
symptoms as ‘true’. This adds evidence to the predictive associations for index scores 
found in this study. To our knowledge, this is the first study to test whether false 
knowledge was associated with participant characteristics.  
Limitations: 
There are several limitations to this study that must be noted. First, our sample lacked 
racial and ethnic diversity. This limitation is consistent with other studies that use mTurk 
as a platform to collect data.138 Future studies using targeted recruitment can reveal 
whether similar issues persist in groups disproportionately burdened by colorectal cancer. 
Second, due to survey administration restraints, we were not able to assess participants 
unprompted responses to symptoms and risk factors. Unprompted responses have been 
used elsewhere in the literature104,109 and may more closely represent actual knowledge.  
Strengths 
Strengths of this study include a large sample size that allowed us to test multivariable 
associations. The large sample that we studied allowed us to assess the moderating role of 
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age on these associations. Knowledge, especially of a complex disease like CRC, can be 
difficult to contextualize when considering the many participant characteristics that could 
be associated with higher levels of knowledge. Another strength of this study is the 
robust collection of cancer experience and psychological variables. We found that these 
variables remained significantly associated in multivariable models while demographic 
variables did not. Finally, we included false symptoms and risk factors allowing us to test 
whether index scores were true to actual knowledge rather than representing participant 
identification of presented survey items.  
Conclusion 
A large body of literature related to perceptions about colorectal cancer and screening 
exists for individuals age 50+.  We show that age is an important factor to consider when 
assessing predictors of CRC symptom and risk factor knowledge. Because no participants 
in our sample have been screened for colon or rectal cancer before, these differences 
offer some evidence that unscreened people under 50 years old should be considered 
differently than those over 50 in both research and clinical practice. As researchers, 
practitioners, and the public grapple with increasing risk for CRC in younger people, we 
must preemptively build our knowledge around other important constructs in younger 
cohorts of people. In fact, an early impact analysis indicated that there has been 
significant increases in testing in those age 45-49 after the ACS guideline statement was 
released in 2018.139 It is currently difficult for people under 50 to obtain screening that is 
covered by insurance. If the USPSTF recommends that individuals 45-49 should be 
screened, the Affordable Care Act mandates that this testing is covered by the patient’s 
insurance.88,89 Patients even younger than age 45 could potentially seek screening should 
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they choose, leading to over screening. There are downstream consequences of over-
screening and utilization of healthcare resources to conduct potentially invasive and 
costly screening on groups of individuals whose risk remains relatively low compared to 
their older counterparts.72  Innovative solutions involving stratification based on risk 
using technologies such as artificial intelligence to identify those who would benefit most 
from more intensive screening, may help with defining appropriate populations .140 
 If symptoms in younger individuals arise, there must be rapid response from both 
patients and their providers to conduct diagnostic workup to ensure that the diagnosis of 
younger-onset colorectal cancers are not delayed. An individual’s baseline knowledge 
about both risk factors and symptoms will be valuable to assess so that they can make an 
informed decision about the best actions for screening and diagnosis. This study provides 
a base for future work that unravels the complicated contextual factors that influence 
somebody’s knowledge about CRC risk factors and symptoms. 
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Paper 1 Tables  
 
Table 1: Participant Demographics (N=579) 
Continuous Variables Range Mean (SD) 
Age      20-69 48.2 (5.9) 
Health Literacy 5-20 8-20 17.8 (2.48) 
Subjective Numeracy 1-6 1.38-6 4.6 (.94) 
   
Categorical Variables N (%) 
Age  
   18-49 358 (61.8) 
   50+ 220 (38) 
Gender 
 
     Female 357 (61.7) 
Race 
 
     White / Caucasian 480 (82.9) 
     Not-White/Caucasian 99 (17.1) 
Hispanic – Yes 26 (4.5) 
Primary Language English—Yes 573 (99) 
Education categories  
  Highschool or less  96 (16.6) 
  Some college 164 (28.3) 
  College Graduate 189 (32.6) 
 Some Graduate School / Graduate degree  129 (22.3) 
Relationship Status 
 
 Single 212 (36.6) 
 In a relationship / cohabitating  87 (15) 
 Married  278 (48) 
Income 
 
     <30k 112(19.3) 
     30-59,999 181 (31.3) 
     60-89,999 136 (23.5) 
     >90k 149 (25.7) 
Insurance  
 No 93 (16.1) 
 Private 393 (67.9) 




Table 2: Risk Factor and Symptom Identification Full Sample 
Risk Factor Identified as 
risk factor 
N (%) 
Don’t Know  
N (%) 
Identified as not 
a risk factor 
N (%) 
Increased Age 514 (88.8) 49 (8.5) 14 (2.4) 
Obesity/ High BMI 441 (76.2) 110 (19) 28 (4.8) 
A diet high in red or processed 
meats 
448 (77.4) 90 (15.5) 39 (6.7) 
Diabetes 256 (44.2) 263 (45.4) 58 (10) 
IBD/Inflammatory bowel disease 450 (77.7) 106 (18.3) 23 (4.0) 
Heavy Alcohol 306 (52.8) 195 (33.7) 77 (13.3) 
Tobacco use 272 (47.0) 198 (34.2) 109 (18.8) 
Family History 515 (88.9) 44 (7.6) 20 (3.5) 
Correctly Identified Risk Factors 
(0-8) Mean (SD)  
 
5.5 (1.96)   
False Risk Factors    
Exposure to violent video games 13 (2.2) 51 (8.8) 512 (88.4) 
Exposure to sun without sunscreen  44 (7.6) 190 (32.8) 345 (59.6) 
    
False Risk Factors Identified as 
risk factors (yes)  
0 identified 1 identified 2 identified 
 526 (90.8) 46 (7.9) 7 (1.2) 
Symptom Identified as a 
symptom 
N (%) 
Don’t Know  
N (%) 




Blood when you wipe after using 
the bathroom 
497 (85.8) 61 (10.5) 21 (3.6)  
Persistent abdominal pain 429 (74.1) 113 (19.5) 35 (6.0)  
Persistent anemia (paleness, 
weakness, fatigue) 
346 (59.8) 180(31.1) 52 (9.0)  
Unexplained weight loss 399 (68.9) 147 (25.4) 31 (5.4)  
Persistent changes in bowel habits 468 (80.8) 90 (15.5) 21 (3.6)  
Correctly Identified Symptoms 
(0-5) Mean (SD)  
 
3.7 (1.46)    
False Symptoms     
Persistent indigestion or heartburn 152 (26.3) 255 (44) 171 (29.5)  
Frequent urges to urinate  115 (19.9) 252 (43.5) 210 (36.3)  
Frequent headaches 38 (6.6) 281 (48.5) 260 (44.9)  
False Symptoms Identified as 
symptoms (yes)  
0 identified 1 identified 2 identified 3 
identified 





















Non-significant control variables also included in the model: General health, Health Literacy, Confidence in seeking advice about 
medical topics, having a regular medical provider, and relationship status  
Table 3: Multivariable linear regression for correct risk factors  a= significant at .05, b= significant at .01, c= significant at <.001 




  <50 
risk 
factors 
  ≥50 risk 
factors 
  
Variable coding B 95% CI p value B 95% CI p value B 95% CI p value 
Age ≥50 -.010 -.341-.321 .953       
Education More than college 
(ref) 
         
 College grad .036 -.401-.472 .873 .024 -.520-.569 .931 .166 -.629-.961 .680 
 Some college -.052 -.519-.414 .826 .002 -.606-.610 .995 .000 -.775-.776 .999 
 HS or less -.043 -.580-.494 .875 -.257 -.981-.466 .485 .199 -.657-1.055 .647 
Household Income GT90k (ref)          
 60-89,999 -.037 -.505-.430 .875 -.091 -.665-.482 .754 .096 -.758-.951 .824 
 30-59,999 .024 -.458-.506 .921 -.182 -.790-.427 .558 .409 -.427-1.245 .336 
 LT30k -.297 -.931-.337 .358 -.217 -1.045-.610 .605 -.345 -1.421-.732 .528 
Gender Woman vs Man .036 -.306-.379 .835 .085 -.357-.527 .706 .092 -.486-.671 .754 
Race  Other v. white -.261 -.695-.173 .238 -.459 -1.047-.130 .126 .059 -.620-.738 .864 
Insurance Private (ref)          
 Public .586 .055-
1.117 
.031a .102 -.590-.794 .772 1.243 .347-2.140 .007b 
 No -.186 -.683-.312 .464 -.238 -.946-.470 .509 -.151 -.886-.583 .685 
Subjective Numeracy Cont. .284 .098-.470 .003b .336 .088-.583 .008b .142 -.155-.440 .347 
Anybody close died 
of cancer 
Yes v no .170 -.169-.509 .326 .028 -.421-.477 .903 .452 -.107-1.010 .112 
Family, spouse, or 
somebody close 
tested for CRC 
Yes v. no/don’t 
know 
.601 .253-.949 .001b .639 .189-1.089 .006b .510 -.063-1.083 .081 
Self ever diagnosed 
with cancer 
Yes v no -.517 -1.103-
.068 
.083 -.213 -1.027-.600 .606 -.921 -1.818- -
.023 
.044a 
Cancer worry Cont.  .182 .013-.351 .035a .166 -.043-.375 .119 .280 -.027-.588 .074 
Perceived Likelihood 
of cancer 
Cont. .207 .001-.415 .05a .252 -.012-.517 .062 .070 -.293-.433 .703 
Commitment to 
testing 
Cont.  .160 .030-.289 .016 a .167 .001-.332 .048 a .176 -.057-.409 .138 
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Non-significant Control variables also included in the model: General health, Health Literacy, Confidence in seeking advice about medical topics, 
having a regular medical provider, and relationship status
Table 4:  Multivariable linear regression for correct symptom scores  a= significant at .05, b= significant at .01, c= significant at <.001 
 
 
  Overall 
sample 
symptoms 
  <50 
symptoms 
  ≥50 
symptoms 
  
Variable coding B 95% CI p value B 95% CI p value B 95% CI p value 
Age ≥50 .145 -.105-.395 .256       
Education More than college 
(ref) 
         
 College grad -.043 -.372-.286 .797 -.204 -.613-.205 .327 .370 -.234-.973 .228 
 Some college .087 -.266-.440 .628 -.023 -.481-.435 .922 .291 -.300-.883 .332 
 HS or less .005 -.401-.411 .981 .009 -.537-.555 .975 .157 -.497-.812 .636 
Household Income GT90k (ref)          
 60-89,999 -.017 -.370-.335 .923 -.126 -.555-.303 .564 .099 -.552-.750 .765 
 30-59,999 -.201 -.564-.163 .279 -.179 -.637-.279 .442 -.144 -.781-.492 .656 
 LT30k -.371 -.852-.110 .130 -.360 -.982-.262 .256 -.331 -1.159-.496 .431 
Gender Woman vs Man .354 .095-.612 .007b .348 .018-.677 .039a .400 -.044-.843 .077 
Race  Other v. white .133 -.194-.459 .425 -.016 -.459-.426 .942 .316 -.197-.828 .226 
Insurance Private (ref)          
 Public .094 -.309-.497 .647 .220 -.300-.740 .406 -.039 -.731-.653 .912 
 No -.034 -.410-.341 .857 .214 -.319-.747 .430 -.166 -.725-.393 .558 
Subjective Numeracy Cont. .098 -.043-.239 .172 .134 -.053-.321 .159 .002 -.226-.231 .983 
Anybody close died of 
cancer 
Yes .301 .044-.558 .022a .126 -.210-.463 .461 .648 .217-1.079 .003b 
Family, spouse, or 
somebody close tested 
for CRC 
Yes v. no/don’t 
know 
.397 .134-.660 .003b .608 .271-.945 <.000c .078 -.361-.517 .725 
Self ever diagnosed with 
cancer 
Yes -.166 -.610-.277 .462 -.109 -.721-.503 .726 -.274 -.963-.415 .434 
Cancer worry Cont.  .052 -.076-.180 .428 .035 -.122-.192 .660 .127 -.110-.363 .293 
Perceived Likelihood of 
cancer 
Cont. .108 -.049-.265 .176 .216 .017-.415 .033a -.069 -.346-.209 .625 
Commitment to testing Cont. .036 -.063-.135 .473 .061 -.063-.186 .334 -.065 -.245-.116 .481 
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Preferences for Colorectal Cancer Screening Strategies by Age 
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Abstract: 
Introduction: In 2018, the American Cancer Society gave a qualified recommendation 
for individuals age 45-49 to initiate screening for colorectal cancer (CRC). Because 
several screening strategies are recommended, making an informed decision involves 
including an individual’s preferences. Few studies have included individuals under age 
50 due to guidelines recommending initiation of screening at age 50. In this study, we use 
the Analytic Hierarchy Process (AHP) to explore preferences for screening strategies and 
evaluate whether preferences vary by age (<50 and ≥50). Methods: Participants 
evaluated a hierarchy with 3 decision alternatives (colonoscopy, fecal immunochemical 
test, and computed tomography colonography), 3 criteria (test effectiveness, the 
screening plan, and features of the test) and 7 sub-criteria. We used the linear fit method 
to calculate consistency ratios and the eigenvector method to calculate aggregated group 
preferences. We also conducted sensitivity analysis to assess whether results are robust to 
change. We tested differences in preferences by participant variables using chi-square 
and ANOVA. Results: Participants that were either white or have lower health literacy 
were more likely to be excluded due to inconsistency. Colonoscopy was the preferred 
strategy in those under age 50 and FIT was preferred by those over age 50 (p=.002). 
Participants rated test effectiveness as the most important criteria for making their 
decision (weight=.555). Sensitivity analysis showed that our results were robust to shifts 
in criteria and sub-criteria weights. Discussion: The differences that we found by age 
should be considered if adapting screening programs to include individuals under age 50. 
AHP activities can also be incorporated into health systems to ensure that patients are 
making preference-aligned decisions. Costs should be considered when allocating limited 




Colorectal Cancer and Screening Guidelines: 
Colorectal-cancer (CRC) related incidence and mortality is declining in the 
United States and across the globe, primarily due to public health efforts to improve age 
appropriate, guideline-based screening. However, it still remains a leading cancer control 
priority.3–5,72 Recent analyses indicate a concerning trend of increasing risk in individuals 
under age 50.8,72 In 2018, the American Cancer Society updated it’s guidelines for 
colorectal cancer screening to address this trend in younger individuals and made a 
‘qualified’ recommendation that average-risk adults aged 45 or older should begin 
regular screening.3 This is in contrast to other guidelines that primarily endorse CRC 
screening starting at age 50.141 If adopted by the United States Preventive Services Task 
Force (USPSTF), an independent guideline-producing organization whose 
recommendations influence clinical coverage and policy decisions, approximately 19 
million individuals will be added to the eligible CRC screening pool.125 
Preferences for screening strategies: 
There are several effective but different CRC screening strategies that fall broadly 
into either stool-based or structural, visual exams and are conducted at varying screening 
intervals. These strategies differ with respect to characteristics that could influence an 
individual’s preference and adherence to that screening strategy. Recommendations state 
that choice in screening strategy should depend on the individual’s preferences, test 
availability, and the strategy to which the patient is most likely to adhere to and 
complete.3,141 There is a robust literature that explores preferences for screening strategies 
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and it demonstrates high variability in preferences across studies.112 However, because 
guidelines only recently began recommending screening starting at age 50, few studies 
have included younger people and hardly any have explicitly tested differences in 
preferences by age.  
The Analytic Hierarchy Process and Colorectal Cancer Screening 
 Multicriteria Decision Analysis (MCDA) techniques can be used to help 
individuals make complex decisions. As a research tool, MCDA is a valuable means to 
explore underlying preferences on which a decision is based. In a clinical setting, MCDA 
can facilitate decision-making processes and encourage informed and shared decision-
making by helping patients think critically about all available options and their unique 
characteristics.  The Analytic Hierarchy Process (AHP) is a MCDA technique that breaks 
a decision problem into a hierarchical structure and allows a decision maker to focus on 
one aspect of a complex decision at a time.142 The AHP also enables the analyst to 
quantify preferences for decision alternatives and the criteria on which those preferences 
are based. The AHP technique can be used in healthcare decision-making research and 
practice143 in areas such as shared decision-making, healthcare policy and evaluation, and 
human resource planning.144 Individuals are generally willing and able to use AHP for 
decision-making.116,145 AHP can be used for individual level decisions and results across 
individuals can be aggregated into a group decision. Aggregating to the group level 
allows one to compare hierarchy weights across different subgroups to determine if they 
are evaluating the hierarchy differently.     
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Several studies have used AHP to assess preferences for colorectal cancer 
screening strategies.116–118 These studies were successful in the implementation of AHP 
and found that the screening strategy’s effectiveness or ability to detect and prevent 
cancer was paramount in the decision-making process. Of these, only Xu (2015) and 
colleagues included individuals under age 50.117 The mean age of the participants in their 
analytic sample was 56.7 years old but they did not conduct age subgroup analysis to 
assess differences in preferences by age.  
Current Study: 
Current guidelines suggest that any evidence-based screening strategy is better 
than an individual not getting screening and that individuals generally have preferences 
for CRC screening strategies when given a choice.112 Therefore, preferences should be 
assessed and incorporated into the decision-making process to ensure that individuals are 
receiving preference-aligned care. Research that unravels these preferences will give 
providers information to focus clinical interactions on the most important issues for 
younger people. If age differences are found, it could indicate the need to adapt screening 
programs for younger populations to ensure that they are making preference-concordant 
decisions. 
In the current study, we used the Analytic Hierarchy Process to quantify 
preferences for colorectal cancer screening strategies and the criteria on which these 
preferences are based. This study extends the current United States-based AHP work that 
has recruited from clinic samples and has not explicitly tested whether preferences vary 
for individuals under the current recommended screening guidelines. We also tested 
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whether these preferences are related to any key characteristics of participants beyond 




This study was part of a larger study on perceptions about colorectal cancer in 
individuals under age 50. We collected a convenience sample whereby participants self-
selected to participate from Amazon Mechanical Turk (MTurk). MTurk describes itself 
as a crowdsourcing marketplace that leverages a global workforce to complete a variety 
of tasks, including research tasks.127 MTurk workers (Turkers) represent diverse 
individuals from across the globe and previous work with Turkers has shown that they 
produce high quality research data, even when presented with complex behavioral tasks 
that are traditionally conducted in-person.128 We took best- practice measures to ensure 
adequate quality data including requiring workers to have completed tasks with a high 
approval rating and including qualitative responses to screen for automated responses. 
Initial inclusion criteria related to participant characteristics for this study included being 
ages 45-55, living in the United States, and never having been screened for colorectal 
cancer. After an initial collection of 482 participants, we then released the survey to all 
individuals over 18 who met these criteria. Survey data were collected using Qualtrics.126 
Hierarchy Development:  
In this paper screening strategy is defined as the test, the subsequent follow-up to 
an abnormal result, and the regular screening interval for normal results. In subsequent 
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references, criteria will be in bold, sub-criteria will be italicized. The AHP hierarchy 
(Figure 1) was built to include 3 criteria, 6 sub-criteria, and 3 decision alternatives 
(screening strategies). Criteria and Sub-criteria were selected based on a review of prior 
AHP studies and the colorectal cancer screening literature. Criteria included test 
effectiveness, the screening plan, and features of the test. The screening plan includes 
2 sub-criteria: the follow-up possibility and frequency of testing. Features of the test 
included 4 sub-criteria: the possibility of complications, convenience, the preparation, 
and the procedure. We presented 3 distinct screening strategies as decision alternatives: 
colonoscopy every 10 years (an invasive test that allows for direct visualization of the 
colon), fecal immunochemical test (FIT) every year (a stool-based test that detects blood 
in the stool) and computed tomography colonography (CTC) every 5 years (a 
radiographic test).  
AHP assessment 
Survey procedures were approved by the University of Maryland IRB. After 
completing demographic and knowledge survey items, participants read a brief overview 
of colorectal cancer and the importance of screening (Supplemental materials). They 
were also informed that the goal of the activity was to choose a preferred screening 
strategy. Participants then read statements (Supplemental materials) about each strategy 
related to each criteria/sub-criteria at the lowest level of the hierarchy.  
After each description, we asked participants to rank the decision alternative with 
respect to that criteria from (1) Does not fit to (9) Fits extremely well: “When 
considering the (Criteria/Sub-criteria): On a scale from 1 - 9, how well does (Decision 
Alternative) fit your preferences?” Overall, participants made 3 x 7 = 21 direct 
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comparisons for the 3 decision alternatives and 7 criteria/sub-criteria (Test effectiveness, 
follow-up possibility, frequency of testing, possibility of complications, convenience, 
preparation, and procedure). We used direct comparisons on decision alternatives to 
reduce respondent burden and eliminate the risk of rank reversal.142 Participants then 
made pairwise comparisons at each level of the hierarchy to assess which criteria/sub-
criteria was more important for their decision: “When considering the (Criteria/Sub-
criteria): Which is more important for your decision?” Participants were given the option 
to select “Criteria/Sub-criteria 1, Criteria/Sub-criteria 2 or ‘They are both equal’”.  
Participants then ranked their selection on a scale from 1 (very slightly more important) 
to 9 (extremely more important). To assess stated preferences, after the AHP procedure, 
participants were asked: “After completing this exercise, which test for colorectal cancer 
would you choose?”.  
Independent Variables 
Demographic variables included age (1= <50, 2= ≥50); education (1= high school 
or less, 2= some college, 3= college completion, 4=higher than college); household 
income (1= <30k, 2=30k to 59,999, 3=60k to 89,999, 4= >90k); gender identity (1=man, 
2=woman), self-identified primary race (recoded as 1=white, 2=other); type of insurance 
coverage (recoded as 0=no, 1=public, 2=private), relationship status (recoded as 
1=single, 2=dating or cohabitating, but not married, 3=married). We also assessed health 
literacy136 (continuous 4-20); subjective numeracy137 (continuous 1-6); decisional self-
efficacy (DSES, continuous 0-100), and having a regular medical provider (0=no, 1=yes). 
Finally, we explored variables related to cancer experience: having somebody close who 
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has died of cancer (0=no, 1=yes); and family, spouse, or anybody else close having been 
tested for CRC (recoded 0=no/don’t know, 1=yes).  
Statistical Analysis 
We used the pairwise comparisons at each level of the hierarchy to compute 
reciprocal matrices for each set of comparisons. We then used the eigenvector method, 
which relies on the matrices principal eigenvector146 to calculate a ratio scale of priorities 
for criteria/sub-criteria. Weight estimates are calculated by solving the equation: 𝐴•?̂? =
𝜆 𝑚𝑎𝑥 • ?̂?  where A is the matrix of pairwise comparisons elicited from the participant, 
?̂? is its right eigenvector, and 𝜆𝑚𝑎𝑥 is the largest eigenvalue of A. We calculated 
consistency ratios at the criteria level using the Alonso and Lamata linear fit method to 
evaluate how consistently participants were making judgments.147 Lower consistency 
ratios represent more consistent judgments. Participants with consistency ratios (CR) 
higher than 0.18 were excluded from our analysis. To calculate aggregated group 
decisions for criteria and sub-criteria, we used the row geometric mean method (RGMM). 
We assigned participants their individual preferences for decision alternatives based on 
the greatest of the 3 normalized priority weights for decision alternatives. We performed 
Chi- squared for categorical variables and ANOVA for continuous variables to determine 
associations. We conducted sensitivity analysis by varying the weights of the criteria and 
sub-criteria to assess whether observed alternative weightings are sensitive to small 
changes in the group weighting factors. We conducted statistical analysis using SPSS.148 
For AHP analysis, data were imported into Definitive Pro®149, a software product 




Of the 579 individuals surveyed, 556 (96%) provided complete responses to the 
AHP portion of the survey. Of these, 247 (44.4%) participants gave responses consistent 
enough (CR <0.18) to be included in the final analysis. The demographic features for 
included and excluded participants can be found in Table 1. Participants who are either 
white (p=.037) or have lower health literacy (p=.014) were more likely to be excluded 
from the final analysis due to inconsistency. The spread of consistency ratios <0.18 can 
be found in Figure 2. 
Preferences for screening strategy (decision alternatives) 
Group decision 
We used the group decision to compare hierarchies in the overall sample and in 
each age subgroup using the row geometric mean. The aggregated preference for the 
whole sample (Figure 3, n=247) was for colonoscopy, with a normalized preference of 
0.366, followed by FIT (0.335) and CTC (0.299). In the <50 group (n=161), colonoscopy 
was the preferred test (0.375) followed by FIT (0.321) and CTC (.304). In the ≥50 
(n=86), the group preference was for FIT (0.366) followed by colonoscopy (0.345) and 
CTC (.289). 
Individual preferences 
To assess whether the differences we found at the group level were driven by 
participant variables, we assessed individual level preferences for screening tests (Table 
2). The AHP procedure revealed preferences for 239 participants. Eight participants 
(3.2%) scored equally for multiple screening tests or did not prefer any of the tests. Of the 
participants who had preferences, colonoscopy was preferred by 50.6%, 40.6% preferred 
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FIT, and 8.8% preferred CTC.  In the <50 age group, colonoscopy was the preferred 
screening test by 57.7% of participants while, in the ≥50 age group, most participants 
(56.1%) preferred FIT. Chi-square tests revealed significant differences between the 
proportion of individuals who preferred colonoscopy and FIT in the two age groups 
(p=.002). Those with lower health literacy (p=.002) and lower decisional self-efficacy 
(p=.041) were more likely to select the CTC option compared to colonoscopy or FIT. We 
did not find associations between test selection and any other demographic variables in 
our sample. The majority (59.8%) of participants stated preferences that were concordant 
with their AHP-derived preferences.  
Criteria and sub-criteria 
As a group (Figure 3, n=247), the sample weighed test effectiveness as the most 
important criteria for making their decision (0.555) followed by the features of the test 
(0.280) and the screening plan (0.165). For the sub-criteria of the screening plan, they 
rated frequency of testing and the possibility of follow-up as similarly important, at 0.480 
and 0.520 respectively. For features of the test, the procedure was weighted as most 
important (0.318), followed by the possibility of complications (0.305), the convenience 
(0.224) and the preparation (0.153).  
In the under 50 and ≥50 age groups, the relative priority order was similar to the 
larger group for the criteria (effectiveness, screening plan, features) and sub-criteria of 
features of the test (preparation, convenience, complications, procedure). For the sub-
criteria of screening plan, the under 50 group weighed possibility of follow-up (0.499) 
and frequency (0.501) almost equally, while the ≥ 50 age group weighed the possibility of 
follow-up (0.548) as slightly more important than frequency of testing (0.452). Even 
69 
though the relative priority order was similar between groups, and test effectiveness was 
most important for both groups, we found differences in the magnitude of priorities. The 
under 50 age group assigned a relative priority of 0.585 to test effectiveness while the 
≥50 age group assigned it 0.495. The ≥50 age group assigned higher importance to the 
features of the test (0.340) than younger people (0.250). Both age groups rated 
screening plan at approximately .165. 
Ratings of tests by criteria 
The results of direct comparisons of screening strategies by criteria/sub-criteria 
can be found in Table 3. The group (n=247) rated colonoscopy as highest for the criteria 
test effectiveness and screening plan, while they rated FIT as highest for the criteria 
features of the test. For the sub-criteria of screening plan, colonoscopy was rated most 
favorably for both follow-up and frequency. For all 4 sub-criteria of features of the test 
(complications, convenience, preparation, and procedure), FIT was rated highest. The 
highest rated criteria/sub-criteria were stable when the sample was split by age. 
Sensitivity Analysis 
From our prior experience and the colorectal cancer literature, we identified 
bowel preparation as an important barrier to completion of structural colorectal cancer 
screening exams for some individuals.150 To address this, we tested whether increasing 
the weight of preparation would change the weights of decision alternatives. In the 
overall group, we increased the priority of preparation from .153 to .400 and 
subsequently, complications was reweighted from .305 to .220, convenience from .224 to 
.160, and procedure from .318 to .220. These changes had no impact on the order of 
alternative preferences. In fact, they only changed normalized priority scores of each 
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alternative by < ± .5%. We also tested whether our findings were robust to small changes 
in weighting factors at the criteria level. When we tested a 5% reduction in test 
effectiveness (from .555 to .505), with a prorated distribution to the weightings of 
features of the test and screening plan, we saw no changes in the rank order of 
alternatives and minimal (< ±.5%) changes in the normalized priority scores of 
alternatives. 
Discussion: 
Based on our study, colonoscopy was the preferred screening strategy in our 
overall sample, but we found that CTC was preferred more often by participants who had 
lower levels of literacy and decisional self-efficacy. This may be explained by these 
participants defaulting to the ‘middle’ option (between colonoscopy and FIT) when 
unsure about effectiveness, features, and the screening strategy. We also found 
differences in the preferences for screening strategies between the <50 and ≥50 age 
subgroups. Generally, colonoscopy was the preferred strategy for individuals under 50 
and FIT was preferred by those 50 and over. To our knowledge, the only study in the 
literature that explicitly tested preferences by age was conducted by DeBourcy and 
colleagues in 2008.114 In their supermarket sample, they observed a nonsignificant 
(p=.12) but illustrative trend in preferences for colonoscopy versus FOBT (another stool 
based test) by age that are similar to the results of this study. In the under 50 age group, 
44.9% of people in their sample preferred colonoscopy, while 49% ages 50-64, and 
63.6% ages 65-79 preferred colonoscopy. The differences that we found between those 
≥50 and people <50 in this sample are explained by the relative priority assignment to the 
test effectiveness and features of the test criteria. Both age groups rated test 
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effectiveness as most important for making their decision, however, the ≥ 50 age group 
gave features of the test higher priority than the <50 age group. This difference gave FIT 
a higher priority score than colonoscopy when we applied the criteria weighting factors in 
the ≥50 age group. Other studies that have used AHP to explore preferences for 
colorectal cancer screening strategies have similarly found that the test effectiveness is 
the most important criteria for participant’s decisions. Researchers across studies have 
conceptualized and operationalized this criteria in slightly different ways (i.e., preventing 
cancer116, test accuracy117, and sensitivity/specificity118).  
Approximately 60% of participants gave a stated preference that was concordant 
with their AHP derived preference, after completing the AHP exercise. This is similar to 
what Xu, et al. found (.57) in their 2015 study on individuals that had completed both 
colonoscopy and FIT tests.117 The AHP procedure is not created for or intended to 
replace traditional decision-making processes but to provide additional information that 
can be used and revisited when thinking through complex decisions.142 For the remaining 
40% of participants who provided discordant preferences, there could be criteria that we 
did not include in the hierarchy or subconscious thoughts about the screening strategies 
that were otherwise not factored into our AHP model or participant’s judgments that 
warrant further investigation.   
The results of this study can be placed among a body of literature that explores 
preferences for screening strategies. The variability in the results of these studies is likely 
due to how researchers design the descriptions of each test that are presented to 
participants, the population that they recruit including their experience with CRC 
screening, and the screening strategies that the researchers provide as options.93,112,113 We 
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also add to the AHP literature that explores colorectal cancer screening116–118 in the 
following unique ways: 1) we recruited a United States based national sample when other 
US based work has recruited from clinics only; 2) we simultaneously recruited people 
<50 years and ≥50 years old and tested younger age as a predictor of screening strategy 
preferences; 3) our results offer insight into criteria preferences for individuals under 50 
that is not explored elsewhere in the literature; 4) we conducted sensitivity analysis to 
determine if results were robust to changes at the criteria and sub-criteria level; 5) we 
tested whether individual preferences were associated with participant variables; and 6) 
we developed and tested a new hierarchy that can be considered when incorporating AHP 
into colorectal cancer screening decision-making. 
 
Strengths and Limitations: 
A strength of this study is that we were careful to reduce confounding factors that 
could act to influence an individual’s decision-making process such as only including 
participants that have never been screened, the length and reading level of descriptions, 
and the consistency of test characteristics that we described for each strategy 
(Supplemental material). Using the MTurk platform also allowed us to gather data from a 
national sample representing diverse perspectives. However, convenience sampling 
through the MTurk platform is not representative of an average community sample and 
our sample lacked racial and ethnic diversity. Future studies using targeted or 
representative sampling methods can be used to assess whether the associations we found 
remain stable.  
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Participants also responded to pairwise comparisons with a high level of 
inconsistency leading to many participants with high consistency ratios warranting 
exclusion. High consistency ratios are seen in all current AHP work in colorectal cancer 
screening. Xu and colleagues (2015) excluded 26% for inconsistent judgments in their 
sample who had already completed both FIT and colonoscopy.117 Dolan (2012) and 
Hummel (2013) also report that many participants in their samples were excluded for 
consistency with 22% and 74% excluded respectively.116,118 Inconsistency can be 
explained in several ways. Participants may have never thought about or formulated 
preferences for choosing a screening strategy for CRC. An individual who is still 
formulating preferences may not judge comparisons in a highly consistent manner. 
Alternatively, the online, self-guided nature of the data collection instrument may have 
made it more difficult for participants to consistently judge a hierarchy with multiple 
levels. This could be mitigated by using tools that streamline the process by guiding 
patients through the pairwise comparisons. 
Clinical Implications / Conclusions (future directions) 
In this study, we found differences in the preferences for screening strategies by 
age. To our knowledge, this is the first study designed with the intended purpose of 
exploring whether people under 50 think differently about CRC screening strategies than 
their older counterparts. This information has policy implications and, with further 
evidence, could be used to reevaluate current screening programs to incorporate people 
under age 50. Of note, participants under the age of 50 in this sample preferred the 
screening strategy with the highest associated costs even though these individuals have 
the lowest age-based risk. This finding aligns with the concerns of some opponents of 
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widening the screening age13,83 and should be given attention when considering how to 
allocate limited resources, especially if resources must be diverted from populations with 
the highest absolute risk (those over 50).85  Future work can explore other facets of the 
colorectal cancer screening process that may differ in people under age 50 and whether 
these differences will influence clinical care.  
A key component to shared decision-making is that an individual’s preferences 
are elicited and incorporated into the decision.23 In a healthcare setting, an AHP activity 
similar to the one conducted in this study can be used by individuals to assist the 
formulation of preferences for a particular screening strategy. Doctors or practitioners can 
use the information derived from such an activity to address patient understanding or 
target appropriate information to the things that matter most to individuals. Future work 
should incorporate the lessons learned from this study and previous work using AHP to 
build tools that can be integrated in a healthcare system to help younger individuals make 





































Categorical Variables Included 
Subjects 









Age                                            18-49 160 (65) 190 (61.5) .389 
   50+ 86 (35) 119 (38.5)  
Gender                                  Woman 157 (63.6) 182 (58.9) .256 
      Man 90 (36.4) 127 (41.1)  
Race                      White / Caucasian 198 (80.2) 268 (86.7) .037 
     Not white/Caucasian 49 (19.8) 41 (13.3)  
Education categories        HS or less 45 (18.2) 51 (16.6) .474 
  Some college 65 (26.3) 88 (28.6)  
  College graduate 88 (35.6) 95 (30.8)  
Some graduate school /                    
Graduate degree 
49 (19.8) 74 (24.)  
Relationship                            Single 93 (37.7) 110 (35.8) .769 
Relationship / cohabitating 35 (14.2) 50 (16.3)  
                                Married  119 (48.2) 147 (47.9)  
Income                                       <30k 52 (21.1) 54 (17.5) .472 
     30k to 59,999 72 (29.3) 102 (33)  
     60k to 89,999 63 (25.6) 70 (22.7)  
     >90k 59 (24) 83 (26.9)  
Insurance No 38 (15.4) 48 (15.7) .751 
 Private 166 (67.2) 212 (69.3)  
                                     Public 43 (17.4) 46 (15.0)  
Continuous Variables Mean (SD) Mean (SD) ANOVA 
Health Literacy 18.15 (2.2) 17.63 (2.7) .014 
Subjective Numeracy 4.59 (.97) 4.67 (.90) .302 
Decisional self-efficacy 82.2 (16) 80.0 (15.9) .107 
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Table 2: Preferences for screening tests from AHP. 





































Full Sample with 
preference (N=239) 
121 (50.6) 21 (8.8) 97 (40.6)  
Categorical Variables N(%) N(%) N(%)  
  Age                         <50 90 (57.7)a 15 (9.6) 51 (32.7)a .002 
50+ 31 (37.8)b 5 (6.1)  46 (56.1)b  
Gender Woman 73 (48.3) 10 (6.6) 68 (45) .100 
Man 48 (54.5) 11 (12.5) 29 (33)  
Race White/ Caucasian 100 (51.5) 14 (7.2) 80 (41.2) .205 
Not white/Caucasian 21 (46.7) 7 (15.6) 17 (37.8)  
 Education      HS or less 19 (43.2) 7 (15.9)  18 (40.9) .581 
  Some college 33 (52.4) 3 (4.8)  27 (42.9)   
 College graduate 42 (50.6) 7 (8.4)  34 (41)   
Some graduate school /                    
Graduate degree 
27 (55.1) 4 (8.2)  18 (36.7)   
 Relationship          Single 41 (45.6) 10 (11.1) 39 (43.3) .396 
   Relationship/cohabitating 15 (42.9) 3 (8.6) 17 (48.6)  
                      Married  65 (57) 8 (7) 41 (36)  
Income                       <30k 25 (50) 3 (6) 22 (44) .548 
     30k to 59,999 30 (44.1) 5 (7.4) 33 (48.5)  
     60k to 89,999 32 (52.5) 8 (13.1) 21 (34.4)  
     >90k 33 (55.9) 5 (8.5) 21 (35.6)  
Insurance                      No 16 (45.7) 1 (2.9) 18 (51.4) .277 
 Private 88 (54) 15 (9.2) 60 (36.8)  
  Public 17 (41.5) 5 (12.2) 19 (46.3)  
Regular Provider        Yes                               79 (54.5) 13 (9.0) 53 (36.6) .276 
No 42 (44.7) 8 (8.5) 44 (46.8)  
Family, spouse,      Yes 
other close tested  
for CRC 
86 (51.8) 12 (7.2) 68 (41) .434 
No 35 (47.9) 9 (12.3) 29 (39.7)  
Anybody close      Yes 
ever died of cancer 
76 (56.7) 11 (8.2) 47 (35.1) .099 
No 45 (42.9) 10 (9.5) 50 (47.6)  
Continuous Variables Mean (SD) Mean (SD) Mean (SD) ANOVA 
Health Literacy 18.2 (2.0) 16.6 (3.1) 18.4 (2.0) .002 
Numeracy 4.6 (.96) 4.2 (1.0) 4.6 (.98) .205 
Decisional self-efficacy  82.9 (15.5) 74 (17.4) 83.6 (15.4) .041 
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Figure 3: Group decision weighting factor results N=247 
  
80 






























Test effectiveness Colonoscopy 0.417 0.415 0.421 
 FIT 0.284 0.281 0.292 
 CTC 0.299 0.304 0.287 
Screening Plan Colonoscopy 0.425 0.436 0.403 
 FIT 0.279 0.263 0.310 
 CTC 0.296 0.301 0.287 
Follow up Colonoscopy 0.456 0.468 0.432 
 FIT 0.277 0.262 0.308 
 CTC 0.267 0.270 0.260 
Frequency Colonoscopy 0.397 0.410 0.372 
 FIT 0.280 0.264 0.312 
 CTC 0.323 0.326 0.316 
Features of the test Colonoscopy 0.218 0.230 0.197 
 FIT 0.481 0.464 0.513 
 CTC 0.301 0.306 0.290 
Complications Colonoscopy 0.200 0.210 0.179 
 FIT 0.520 0.505 0.554 
 CTC 0.280 0.285 0.267 
Convenience Colonoscopy 0.176 0.185 0.156 
 FIT 0.488 0.477 0.508 
 CTC 0.336 0.338 0.336 
Procedure Colonoscopy 0.266 0.279 0.241 
 FIT 0.413 0.393 0.453 
 CTC 0.321 0.328 0.306 
Preparation Colonoscopy 0.217 0.228 0.196 
 FIT 0.548 0.535 0.572 
 CTC 0.235 0.237 0.232 
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Chapter 5: Screening for colorectal cancer in individuals age under 50: 
decisional self-efficacy and desired role in decision-making  
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Introduction: Shared decision-making (SDM) is a decision-making where a doctor and 
their patient collaborate on a decision about the patient’s healthcare. Shared decision 
making is appropriate when there is uncertainty surrounding a decision or when the 
outcomes of each option are relatively equal. Due to increasing risk, the American 
Cancer Society updated their recommendations to include individuals age 45-49 for age 
based colorectal cancer screening. Because of the uncertainty surrounding this issue, a 
shared decision-making framework is appropriate for this age group. A key component of 
shared decision-making is that individuals are participating in the process at their desired 
level. In this study, we evaluate people under age 50, their desired role in decision 
making and their self-efficacy for making decisions about colorectal cancer screening. 
Methods: We recruited 579 participants from Amazon Mechanical Turk (MTurk) for a 
survey on perceptions about colorectal cancer screening. We evaluated participants 
desired role in general medical decision making as well as whether to get screened for 
colorectal cancer and with which screening test to use with a modified control 
preferences scale (CPS). We used the Decisional Self-Efficacy Scale (DSES) to evaluate 
participant’s self-efficacy for making these decisions. We used multinomial logistic 
regression and linear regression models to evaluate age as a predictor of the CPS and 
DSES. Results: We found that being under age 50 was associated with a desire for 
shared or passive role (compared to active) in decisions about getting screened (p<.000) 
for colorectal cancer and with which screening strategy to use (p=.001). We did not find 
age to be associated with decisional self-efficacy. Discussion: If we incorporate younger 
people into screening programs for colorectal cancer, a shared decision-making 
framework is appropriate. However, we must be mindful that younger people may want 






Shared decision-making (SDM) is a process between a patient and clinician with 
the goal of making an informed and joint decision about the patient’s healthcare.17,19,151 A 
shared decision-making model (compared to physician driven) is beneficial because 
patients that are engaged in their healthcare decision-making typically have higher levels 
of satisfaction with their care and can have better outcomes.152 Shared decisions are 
appropriate when there is a decision to be made between options with similar outcomes, 
when there is a high level of uncertainty between options, or when options are highly 
preference sensitive because the outcomes of the decision are relatively equal. 4  
Colorectal Cancer 
The overall incidence and mortality of colorectal cancer (CRC) are declining in 
the United States.8,72 Reductions in CRC incidence and mortality are primarily attributed 
to the uptake of screening according to guidelines based on age.4 The United States 
Preventive Service Task Force (USPSTS), an independent policy recommending 
organization whose recommendations guide clinical care, has recommended that 
individuals at average risk of developing CRC should begin screening at age 50.153 
However, recent analysis using the Surveillance, Epidemiology, and End Results (SEER) 
database show that the risk of both colon and rectal cancer in the United States are 
increasing in individuals under age 50.8 Due to this shift, in 2018, the American Cancer 
Society gave a qualified recommendation  for individuals age 45-49, at average risk, to 
initiate screening for CRC.3  
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  In light of these new recommendations, a shared decision-making framework is 
appropriate for colorectal cancer screening in individuals age 45-49 because any 
screening strategy is recommended over no screening and strategy selection (stool based 
or structural exam) is highly sensitive to an individual’s preferences.23 Evidence also 
suggests that shared decision-making in colorectal cancer screening leads to higher 
intention to be screened and higher satisfaction with the decision-making process.93 
Desired Role in Decision-making and Decisional Self-Efficacy 
Shared decision-making between individuals and their doctor require that the 
individuals are participating in the decision at their desired level.19 An assessment of 
patient willingness to participate in decision-making is also a critical component of the 
SDM process.19 There may be considerable variation in an individual’s desired role. A 
2012 systematic review of 115 studies on shared decision-making preferences in patients 
found that, in 63% of studies assessed, shared decision-making was the majority 
preference while, in 21% of studies, physician delegated decision-making was preferred 
by the majority of participants.120 Desired role has been studied in the context of 
colorectal cancer screening.93,94,123 However, none of these studies measured both general 
and situation specific role preferences nor did they sample individuals who were under 
the age of 50, so very little information is available regarding these individuals’ 
preferences for participating in the colorectal cancer screening decision-making process.  
If individuals desire to be involved in the decision-making process, it follows that 
they must also have the self-efficacy for making decisions about their healthcare. Self-
efficacy is a central health behavior construct and is important for health behaviors across 
multiple domains such as cigarette smoking, exercise and weight control, and alcohol 
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use.154  If self-efficacy and desired role are mismatched, tools can be built to increase 
self-efficacy for making decisions,155 thus, empowering patients and improving 
satisfaction with the screening process and their subsequent adherence to a screening 
strategy. 
Current Study: 
Younger age may play a role in desired role in the decision-making process. A 
review on shared decision-making found that younger and more highly educated 
individuals tended to desire more involvement in making medical decisions.152 However, 
colorectal cancer may not be on younger people’s ‘radar’ and uncertainty and lack of 
clarity on guidelines and screening modalities, may influence patients to defer decisions 
to their doctors. No work, to our knowledge, has assessed the desired role and self-
efficacy for making CRC screening decisions in individuals under the age of those that 
historically would be screened. In this study, we explored whether the desired role in 
decision-making varies for individuals under age 50 compared to those who are over age 
50. We also evaluated predictors of decisional self-efficacy in our sample to evaluate 
targets for interventions to increase individual’s confidence in making medical decisions.  
Methods: 
Sample: 
This study was part of a larger study on perceptions about colorectal cancer in 
individuals under age 50. Survey data were collected using Qualtrics126 after participants 
self-selected to participate from Amazon Mechanical Turk (mTurk). We took best- 
practice measures to ensure high quality data including requiring workers to have 
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completed tasks with a high approval rating and including qualitative responses to screen 
for ‘bots’ or automated responses. Inclusion criteria for this study included being age 
18+, living in the United States, and never having been screened for colorectal cancer.  
Measures: 
Dependent Variables: 
Desired role was measured using a modified Control Preferences Scale (CPS) (Table 
1).156 Participants were asked a single question about their general medical decision role 
preference and also 2 scenario specific role preferences for the decision to get screened 
for colorectal cancer and the decision of which test to get.  Responses to these questions 
were collapsed into Patient driven (Active) (1), collaborative/shared (2), and Doctor 
driven (Passive) (3) roles.  
Decisional self-efficacy was measured using the decisional self-efficacy scale (DSES).28 
The 11-item DSES measures one’s confidence in their decision-making abilities in the 
context of general medical decision-making on 5-point Likert scales (0-4).  
Items are averaged and then transformed for a final scale score range of 0-100.  
Independent Variables: Demographic variables included: age (1= <50, 2= ≥50); 
education (1= Highschool or less, 2= some college, 3= college completion, 4=higher than 
college); household income (1= <30k, 2=30-59,999, 3=60-89,999, 4= >90k); gender 
identity (1=man, 2=woman), self-identified primary race (recoded as 1=white, 2=other); 
type of insurance coverage (recoded as 0=no, 1=public, 2=private, relationship status 
(recoded as 1=single, 2=dating or cohabitating but not married, 3=married). We also 
assessed general health (continuous 1=Poor, 5=excellent); health literacy136 (continuous 
4-20); subjective numeracy137 (continuous 1-6); and having a regular medical provider 
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(0=no, 1=yes) as independent variables. Finally, we included independent variables 
related to cancer experience: having somebody close who has died of cancer (0=no, 
1=yes); family, spouse, or anybody else close having been tested for CRC (recoded 
0=no/don’t know, 1=yes); self being diagnosed with cancer (0=no, 1=yes); worry about 
cancer (continuous 1=not at all, 5=extremely); perceived likelihood of getting cancer (1= 
very unlikely, 5= very likely); and stage of commitment to CRC testing (1=have not 
thought about getting tested-5=committed to getting tested).  
Analysis: 
We used descriptive statistics to evaluate the prevalence of each role preference for 
general medical decisions, the decision to get screened (GS), and the decision of which 
screening strategy to use (WS). We then calculated bivariate statistics using GS and WS 
as dependent variables. We then entered variables that were significant at the bivariate 
level (p<.10) into a multinomial logistic regression using the 3 nominal categories as 
outcomes (active, passive, shared roles). We used the active (patient driven) role as the 
reference category. We calculated Cronbach’s alpha for the DSES. We then conducted 
multiple regression to determine multivariable associations with independent variables 
and the DSES. Because this analysis was exploratory, we used a backwards stepwise 
procedure with p>.10 as a cutoff for removal. We conducted all analysis using 
SPSSv25.148 
Results: 
Sample demographics:  
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The sample was majority women (61.5%), white/Caucasian (82.9%), used 
English as their primary language (99%), born in the United States (96.2%), and married 
(48.2%). Approximately 54.9% of the sample had completed a college degree or above 
and most participants were insured with either private (67.9%) or public insurance 
(15.5%). 
Preferred Role (control preferences scale):  
For general medical decisions, 57.5% of the sample preferred a patient driven 
(active role), 32.6% preferred a shared role, and 9.8% preferred a doctor driven (passive 
role). For the decision of whether to get screened 57.8% preferred a patient driven (active 
role), 27.7% preferred shared, and 14.5% preferred doctor driven (passive). For deciding 
which screening strategy to use, 53% preferred active, 25.9% preferred shared, and 
21.1% preferred the passive role. Participants’ general role preference was highly 
associated with their role preferences for both the decision to get screened (GS) for 
colorectal cancer (p<.000) and for the decision about which screening strategy (WS) they 
would use (p<.000) (Table 2). Participants switched role preference from the general 
decision to each of the situation specific decisions between 4.5% and 24.3% of the time.  
Bivariate Statistics: 
Bivariate Statistics can be found in Table 3. Briefly, we found age; gender; having 
a family member, spouse, or anybody else close ever tested for CRC; anybody close ever 
died of cancer; cancer worry; and commitment to testing were significantly associated 
with role preference for the decision to get screened (GS) at the p=.05 level. We also 
found that relationship status, health literacy, and perceived likelihood of cancer were 
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significantly associated with role preference for GS at the .10 level. For what screening 
strategy to use (WS), we found age, gender, health literacy, perceived likelihood of 
getting cancer, cancer worry, and commitment to testing were significantly associated 
with role preference at the .05 level. At the .10 significance level, we found decisional 
self-efficacy, to be associated with the role preference for WS. 
Multinomial Logistic Regression: 
The results of both adjusted multinomial logistic regression models can be found in Table 
4. All multinomial results use the patient driven (active role) as the reference category.   
Whether to get Screened 
For the decision about whether to get screened, compared to the patient driven 
(active role) (reference category), individuals in the <50 age group (compared to ≥50) 
were more likely to prefer the shared role (OR=1.904, p=.003) and the passive role 
(OR=3.087, p<.000). For shared role preference compared to active, we also found 
significant associations for men (OR=.646, p=.049), higher cancer worry (OR=1.276, 
p=.027), and higher commitment to testing (OR=1.297, p=.002). For passive role 
preference compared to active, we found significant associations for not having 
somebody close tested for CRC (OR= 1.947, p=.018), higher cancer worry (OR=1.351, 
p=.029), and higher commitment to testing (OR=1.449, p=<.000).  
What screening strategy to use  
For the decision about what screening strategy to use, compared to the patient 
driven (active role) (reference category), individuals in the <50 age group (compared to 
≥50) were more likely to prefer the shared role (OR=1.649, p=.022) and the passive role 
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(OR= 2.233, p=.001).  For shared role preference compared to active, we also found 
significant associations for higher cancer worry (OR=1.296, p=.019) and higher 
commitment to testing (OR=1.261, p=.005). For passive role preference compared to 
active, the only other variable that remained significant in the adjusted model was 
commitment to testing (OR=1.301, p=.004). 
Decisional Self Efficacy: 
The internal reliability of the DSES scale was α= .92. Since we did not find that the 
DSES score was associated with desired role preference for either the decision to get 
screened or the decision for which screening strategy to choose, we conducted an 
exploratory analysis to evaluate predictors of the DSES using a backwards, stepwise, 
multiple linear regression. The results of the regression model can be found in Table 5. 
We did not find decisional efficacy was associated with age. However, we found 
significant associations between higher scores on the DSES and having high school or 
less education (p=.011); having a regular doctor (p=.012);  higher subjective numeracy 
(p=.001); higher health literacy (p<.000); and higher general health (p<.000). 
Discussion: 
In our sample, we found that an active role was preferred by our participants more 
often than the shared or passive role for all three decisions that we evaluated. These 
results contrast with other studies in the literature that explored role preference in the 
context of colorectal cancer screening. In a sample of primarily white individuals, 45% 
preferred decision-making for CRC to be shared with the doctor, 25% desired to be the 
primary decision maker (after considering the doctor’s opinion), 16% preferred the doctor 
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to make the decision, and 15% preferred to make the decision on their own.94 In a study 
on a novel decision aid for shared decision-making, Schroy and colleagues (2011) found 
that in their primarily African American sample that patients desired role in “decision-
making” was primarily shared (53.3%) followed by mostly patient (27.5%) and then 
mostly doctor (19.2%).93 In a primarily Hispanic sample, a collaborative role for 
decisions about health was preferred by 53.3% of participants while passive was 
preferred by 26.4% and active by only 20.3%.123 While other studies have evaluated 
desired role in this context, our study is unique because we collected a national sample 
over the internet as well as our inclusion of individuals under age 50. 
We found that age is associated with role preference in the decision to be screened 
for CRC and for deciding which screening strategy to use. Contrary to findings by Frosch 
and Kaplan152, who find that younger age is associated with desiring an active or shared 
role, in our sample people <50 would prefer a shared or passive role. These results could 
indicate that those under age 50 have not yet begun to consider CRC screening, 
increasing the likelihood for them to want to talk through and make a shared decision 
with their doctor or simply defer those decisions all together. Alternatively, younger 
individuals may not feel that they have enough information to take the patient-driven 
role. Regardless, clinicians should clarify the role that patient’s would like to take in the 
decision-making process and attempt to match patient’s preferred style with the care that 
they deliver.157  We also found other participant characteristics were associated with 
desired role that will be useful for future work that explores these two decisions e.g. male 
participants prefer active over shared for deciding whether to get screened. 
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In our sample, role preference was only stable from general medical decisions to 
the decision to get screened and the decision of which screening strategy to use between 
56.1%-84% of the time. This aligns with concerns that researchers should be careful 
appropriately conceptualize, represent, and thus appropriately measure the construct of 
interest whether it be the more stable role “style”, as intended by the original scale 
developers, or the “situation specific” role preference.158  In our sample, role preference 
for these two decisions share some associations like age, worry about cancer and 
commitment to testing but differ for others such as not having somebody close who has 
tested for CRC is only predictive for the passive role for the decision to be screened and 
not for which strategy to use. This raises important questions about whether researchers 
should evaluate role preference for each decision of interest versus more broadly.  
We did not find that the decisional self-efficacy scale (DSES) was associated with 
role preference. This is evidence that desired role in the CRC decision-making process 
may not be a question of efficacy. However, several variables were associated with 
decisional efficacy, which point to ways that researchers and clinicians can identify 
targets for interventions that improve efficacy, namely those without a regular doctor, 
those with lower health literacy, lower numeracy, and lower self-reported general health. 
This association between those with the lowest education in our sample displaying the 
highest levels of decisional self-efficacy in the adjusted models warrants further 
investigation.  
Limitations: 
This study has several limitations that must be addressed when interpreting 
results. First, the cross sectional, exploratory nature of this study did not allow us to 
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determine whether role preference or efficacy are related to CRC screening behavior. 
Future work with under 50 samples should explore whether these relationships will 
influence clinical care. Second, our sample lacked racial and ethnic diversity. This 
limitation is consistent with other studies that use mTurk to collect data.138 Evaluating 
these associations with more diverse samples who are disproportionately burdened by 
colorectal cancer will reveal whether these associations are stable. Finally, we asked a 
sample of the general public that had never been screened for colorectal cancer what their 
desired roles are in these decision-making processes. These expressed roles may not 
accurately reflect the role that a patient may want during an actual clinical encounter. 
However, we predict that these associations would be stronger in a clinical sample, rather 
than weaker. 
Strengths: 
The conclusions drawn from our study are strengthened by several factors. First, 
we measured role preference for general medical decisions, deciding whether to get 
screened, and for deciding which screening strategy to use. Using these three different 
measures allows us to tap into the stable and situation specific role preferences that many 
other studies do not differentiate between.158 Another strength of our study is our large 
sample size and the robust collection of cancer experience variables that we included in 
our multi-variable models. Adjusting for these variables gives us confidence that the 
associations that we found between age and role preference are not spurious findings.  
Clinical Implications/Conclusions: 
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If new recommendations for individuals age 45-49 are adopted by the USPSTF, 
this will add approximately 19 million individuals to the eligible screening pool and even 
more that will be approaching the age of screening.125 Clinicians will have to decide the 
best way to approach the subject of screening with their patients, which should include 
discussions about their desired role in decision-making if using a shared decision-making 
framework. In order to reap the benefits of patients’ engagement in the decision-making 
process, such as satisfaction, intention to be screened, and ultimately, adherence to the 
chosen screening strategy, care should be tailored to include patients at their desired 
level.  
We have shown that younger age is associated with passive role preference for 
both the decision to be screen and for the decision of which screening strategy to use in 
our national sample. These results are not surprising because people under 50 have not 
been targets of long-standing public health messages that have encouraged people over 
50 to initiate screening. If we are to incorporate younger people into screening programs, 
building appropriate tools to engage these individuals will be necessary. 
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The following statements are about the role you feel 
you and your doctor should have in making 
decisions about …  
 
1. … your health  
2. …about whether you should get screened for 
colorectal cancer. 
3. … about what screening strategy for colorectal 
cancer you should get. 
 
Which of the following best describes what you 
think: 
Coding 
I prefer to make the decision about which treatment 
I will receive 
Patient Driven Role (active 
role) (1) 
I prefer to make the final decision about my 
treatment after seriously considering my doctor’s 
opinion 
Patient Driven Role (active 
role) (1) 
I prefer that my doctor and I share responsibility for 
deciding which treatment is best for me 
Collaborative/Shared Role 
(2) 
I prefer that my doctor makes the final decision 
about which treatment will be used, but seriously 
considers my opinion 
Physician Driven Role 
(passive role) (3) 
I prefer to leave all decisions regarding treatment to 
my doctor 
Physician Driven Role 
(passive role) (3)  


































84 11.4 4.5 79.3 10.2 10.5 
Shared 
General 
22.2 61.4 16.4 19.6 56.1 24.3 
Passive 
General 
22.8 10.5 66.7 10.5 17.5 71.9 




 Whether to get screened (GS) With what screening strategy to use (WS) 




















Age                                        <50 183 (51.1) 109 (30.4) 66 (18.4) <.000c 170 (47.4) 100 (27.9) 89 (24.8) .001b 
≥50 151 (68.6) 51 (23.2) 18 (8.2)  137 (62.3) 50 (22.7) 33 (15.0)  
Education                                       
HS or Less 
56 (58.9) 27 (28.4) 12 (12.6) .441 52 (54.2) 24 (25.0) 20 (20.8) .166 
Some college 103 (62.8) 43 (26.2) 18 (11.0)  95 (57.9) 42 (25.6) 27 (16.5)  
College graduate 108 (57.1) 48 (25.4) 33 (17.5)  96 (50.8) 42 (22.2) 51 (27.0)  
Some graduate/grad school 67 (51.9) 41 (31.8) 21 (16.3)  64 (49.6) 41 (31.8) 24 (18.6)  
Income                                                    
LT30k  
76 (67.9) 22 (19.6) 14 (12.5) .116 66 (58.9) 26 (23.3) 20 (17.9) .214 
30-59,999 107 (59.4) 45 (25.0) 28 (15.6)  90 (49.7) 42 (23.2) 49 (27.1)  
60-89,999 75 (55.1) 43 (31.6) 18 (13.2)  75 (55.1) 39 (28.7) 22 (16.2)  
GT90k 75 (50.3) 50 (33.6) 24 (16.1)  75 (50.3) 43 (28.9) 31 (20.8)  
Gender                                                 
Woman 
202 (57.1) 110 (31.1) 42 (11.9) .013a 193 (54.4) 102 (28.7) 60 (16.9) .006b 
Man 131 (59.0) 49 (22.1) 42 (18.9)  113 (50.9) 48 (21.6) 61 (27.5)  
Race White / Caucasian 284 (59.3) 128 (26.7) 67 (14.0) .273 261 (54.4) 119 (24.8) 100 (20.8) .303 
Not white/Caucasian 50 (50.5) 32 (32.3) 17 (17.2)  46 (46.5) 31 (31.3) 22 (22.2)  
Relationship status Single 132 (62.3) 44 (20.8) 36 (17.0) .084 117 (55.2) 48 (22.6) 47 (22.2) .388 
Dating/cohabitating 50 (58.1) 26 (30.2) 10 (11.6)  45 (51.7) 20 (23.0) 22 (25.3)  
Married 152 (54.7) 88 (31.7) 38 (13.7)  145 (52.2) 81 (29.1) 52 (18.7)  
Insurance                                                     
No 
64 (68.8) 19 (20.4) 10 (10.8) .229 57 (61.3) 21 (22.6) 15 (16.1) .538 
Public 50 (56.2) 27 (30.3) 12 (13.5)  46 (51.1) 24 (26.7) 20 (22.2)  
Private 220 (56.0) 111 (28.2) 62 (15.8)  203 (51.7) 104 (26.5) 86 (21.9)  
Anybody close ever tested for 
CRC         Yes   
226 (58.2) 115 (29.6) 47 (12.1) .04a 209 (53.9) 98 (25.3) 81 (20.9) .831 
No 108 (56.8) 45 (23.7) 37 (19.5)  98 (51.3) 52 (27.2) 41 (21.5)  
Have regular doctor                                  
Yes 
191 (54.7) 106 (30.4) 52 (14.9) .149 175 (50.0) 101 (28.9) 74 (21.1) .105 
No 143 (62.4) 54 (23.6) 32 (14.0)  132 (57.6) 49 (21.4) 48 (21.0)  
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Anybody close ever died of 
cancer Yes 
183 (55.0) 106 (31.8) 44 (13.2) .031a 172 (51.7) 95 (28.5) 66 (19.8) .230 
No 151 (61.6) 54 (22.0) 40 (16.3)  135 (54.9) 55 (22.4) 56 (22.8)  
Ever been diagnosed with 
cancer Yes 
26 (53.1) 14 (28.6) 9 (18.4) .688 26 (53.1) 12 (24.5) 11 (22.4) .956 
No 307 (58.1) 146 (27.7) 75 (14.2)  280 (52.9) 138 (26.1) 111 (21.0)  
Continuous Variables Mean (SD) Mean (SD) Mean (SD) p-value 
ANOVA 
Mean (SD) Mean (SD) Mean (SD) p-value 
ANOVA 
Decisional self-efficacy 81.59 (16.07) 79.39 (16.84) 79.29 (14.32) .262 82.00 (16.19) 79.42 (16.20) 78.75 (15.35) .097 
General Heath 3.36 (.96) 3.43 (.87) 3.45 (.94) .594 3.40 (.96) 3.40 (.86) 3.35 (.96) .881 
Health Literacy 17.98 (2.44) 17.8 (2.35) 17.27 (2.83) .062 18.13 (2.25) 17.58 (2.58) 17.41 (2.83) .009b 
Numeracy 4.66 (.94) 4.54 (.95) 4.64 (.99) .443 4.67 (.94) 4.54 (.99) 4.63 (.92) .420 
Likelihood of cancer 3.13 (.95) 
 
3.32 (.90) 3.13 (.93) .080  3.08 (.97) 3.28 (.90) 3.32 (.84) .021a 
Worry about cancer 2.46 (1.08) 2.88 (1.14) 2.86 (1.08) <.000c 2.43 (1.08) 2.87 (1.13) 2.84 (1.08) <.000c 
Commitment to testing 2.47 (1.28) 2.90 (1.37) 2.92 (1.37) <.000c 2.47 (1.31) 2.85 (1.31) 2.84 (1.37) .003b 
 




 Whether to get screened With what screening strategy to use 

















95% CI p 
value 
Age          <50 vs ≥50 1.904 1.248-2.906 .003b 3.087 1.710-5.573 <.000c 1.649 1.077-2.527 .022a 2.233 1.361-3.662 .001b 
Gender                                                  Man vs 
woman 













CRC       
No vs yes 1.083 .684-1.716 .733 1.947 1.118-3.388 .018a 1.386 .878-2.187 .161 1.274 .768-2.113 .347 
Anybody 
close ever 
died of cancer 
No vs yes .804 .518-1.250 .333 1.086 .626-1.882 .770 .900 .575-1.409 .644 1.382 .848-2.252 .194 
Continuous 
Variables 
             
Decisional 
self-efficacy 
Cont. .989 .975-1.003 .121 .999 .981-1.017 .874 .995 .981-1.010 .523 .990 .974-1.006 .201 
Health 
Literacy 
Cont. 1.036 .939-1.144 .480 .954 .852-1.068 .416 .952 .865-1.048 .318 .977 .879-1.085 .660 
Likelihood of 
cancer 
Cont. .957 .736-1.245 .745 .808 .585-1.116 .196 .996 .766-1.295 .975 1.186 .883-1.591 .257 
Worry about 
cancer 
Cont. 1.276 1.029-1.584 .027a 1.351 1.032-1.767 .029a 1.296 1.043-1.611 .019a 1.268 .996-1.614 .054 
Commitment 
to testing 
Cont. 1.297 1.104-1.523 .002b 1.449 1.183-1.775 <.000c 1.261 1.071-1.484 .005b 1.301 1.085-1.560 .004b 
 
Table 4: Multinomial logistic regression using patient driven (active role) as the reference category a= significant at .05, 





Table 5: Results of the Backwards Stepwise Linear Regression predicting Decisional Self 
Efficacy Scale (DSES) score  
Nonsignificant variables: Race, anybody close tested for CRC, gender, cancer worry, perceived 
likelihood of cancer, ever been diagnosed with cancer, anybody close ever died of cancer, 

















  DSES   
Variable coding B 95% CI p value 
Categorical variables     
Age ≥50 NS NS NS 
Education More than college (ref)    
 College grad -1.051 -4.111-2.009 .500 
 Some college 2.308 -.896-5.512 .158 
 HS or less 4.890 1.125-8.655 .011 
Have regular doctor Yes vs no 3.062 .668-5.456 .012 
Continuous variables      
Health Literacy Cont.  2.915 2.439-3.392 <.000 
Subjective Numeracy Cont. 2.216 .994-3.487 .001 
General health Cont.  2.597 1.352-3.843 <.000 
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Chapter 6: Integrated Discussion 
 
Considering the recent guidelines from the American Cancer Society,3 and the 
rising risk for CRC in people under 508, this project is both timely and appropriate. 
Several studies in the literature have included individuals under 50 and others have 
evaluated age differences in their analysis, but this is the first study, to our knowledge, 
designed to explicitly evaluate the differences between people over 50 and under 50. In 
all 3 manuscripts that were written as part of this dissertation, I found differences by age 
when evaluating shared decision-making constructs. In the following sections I will 
summarize the main findings of the 3 manuscripts, evaluate the strengths and weaknesses 
of this project, and explore the policy and clinical implications of these results.  
6.1 Synopsis of studies and findings 
6.1a  
RQ1: Are people under age 50 able to correctly identify risk factors of CRC? (Paper 1) 
Central to the shared decision-making framework is that an individual (the 
patient) is knowledgeable about the disease about which they are making decisions. 
Additionally, shared decision-making is often thought of as a process. An evaluation of 
the patient’s current knowledge is an important step in this process that builds rapport 
between a patient and doctor team and allows the doctor to fill in the necessary 
knowledge gaps for a patient to make informed decisions.21 
For paper 1, I created 2 indices to assess participants’ knowledge of colorectal 
cancer risk factors and symptoms. Of these, the knowledge of risk factors is more 
proximal to shared decision-making for CRC screening, while knowledge of symptoms is 
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more closely related to diagnostic evaluation of symptomatic individuals. However, both 
constructs are valuable to assess in this context because the gaps in knowledge could 
inform future education programs for people under 50. I evaluated the scores for 
individual items, tested whether knowledge of these two domains differed between the 
two age groups (<50 and ≥50), and tested the moderating role of age in composite 
knowledge scores.  
I found that participants’ knowledge of both risk factors and symptoms were high, 
ranging from 44.2%-88.9% correctly identifying individual risk factors and 59.8%-85.5% 
correctly identifying individual symptoms. For risk factors, participants generally scored 
the lowest for behavioral risk factors like alcohol use (52.8%) and tobacco use (47%). For 
symptoms, participants scored the lowest for symptoms that were related to cancer more 
generally such as persistent anemia (59.8%) and unexplained weight loss (68.9%), rather 
than symptoms specific to gastrointestinal cancers. I found that knowledge scores for 
symptoms and risk factors did not vary in these two age groups. However, I did find 
evidence for age moderating the relationships in multivariable models. Of note, 
predictors of risk factor knowledge in the <50 age group were subjective numeracy, 
knowing somebody close to them who tested for CRC, and commitment to testing 
whereas in the ≥50 age group knowledge of symptoms was predicted by public insurance 
and previous cancer diagnosis. The <50 age group also revealed predictors for symptom 
knowledge including female gender, knowing somebody close tested for CRC, and 
higher perceived likelihood of getting cancer. In the ≥50 group, only knowing somebody 
who has died of cancer remained predictive of symptom knowledge.  
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The results from paper 1 show that, while knowledge of risk factors is generally 
high, there is room for improvement in behavioral risk factors and general symptoms of 
cancer compared to symptoms associated specifically with CRC. Results also provide 
evidence that age might be an important factor when targeting interventions to improve 
knowledge. While I did not find differences in knowledge by age, this paper is the first, 
to my knowledge, to explicitly test the moderating role of age on these knowledge 
constructs. As risk continues to rise in people under age 50, an understanding of 
individuals’ knowledge will be essential to evaluate a starting point for shared decision-
making. The constructs that we have found associated in the <50 group may be 
considered as targets for further research.  
6.1b  
RQ2 What screening strategy do individuals under 50 prefer and on what are these 
preferences based? (Paper 2) 
 Another critical component of shared decision-making is that preferences are 
elicited. In paper 2, I used a technique from decision and operations research called the 
Analytic Hierarchy Process. This technique is a multicriteria decision analysis technique 
that breaks down a complex decision into a hierarchical structure, allowing somebody to 
focus on one small decision at a time. The AHP has been used widely for healthcare 
decision-making and, to my knowledge, three other times in the colorectal cancer 
literature.117,118,143,145 However, we add to the colorectal cancer literature in several novel 
ways (described in Chapter 4).  
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I found that colonoscopy was the preferred strategy in our overall sample. This 
finding adds to a large but inconclusive body of literature that explores test preferences 
across various populations.112 The variability in this literature is likely related to the 
sample studied and how researchers present the details of each screening strategy. A 
strength of this study is that I plan to publish details of descriptions used for each 
screening strategy so that other researchers can evaluate or use them in their own work. I 
also paid careful attention to the length, reading level, parallel structure and equality of 
characteristics described for each strategy (Appendix B). I found that the ‘test 
effectiveness’ was the most important criteria for participants in our sample when 
deciding which screening strategy they would choose. This finding aligns with the other 
studies that have used AHP to explore colorectal cancer screening although each author 
has operationalized this construct differently (i.e., preventing cancer116, test accuracy117, 
and sensitivity/specificity118). I also found that the ‘screening plan,’ including the follow-
up and frequency’ were not as important for participants’ decision-making process.  
The primary contribution to the literature is that I tested the AHP derived 
preferences by age groups (<50 and ≥50). This is the first study, to my knowledge, that 
was designed with this framing and intent in mind. I found that people under age 50 were 
more likely to prefer colonoscopy, while people over age 50 were more likely to prefer 
the FIT option. The differences that I found were statistically significant (p=.002). I also 
found that individuals’ AHP derived preferences matched their stated preference, after 
going through the activity, about 60% of the time.  
A shared decision-making framework is most appropriate when the decision to be 
made is preference dependent, meaning the outcomes are either uncertain or in relative 
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equipoise based on risks and benefits. Colorectal cancer screening for individuals age 45-
49 represents these criteria and the results of this study will be valuable as a springboard 
for future work in this area. Results pointing to the association between younger age and 
preference for colonoscopy must be replicated. At the time of writing this dissertation 
(October 2020) this manuscript is under review with the journal BMC Health Services 
Research. 
6.1c  
RQ3: When making CRC screening decisions, what level of control (role preference) do 
people under 50 prefer and do they feel confident in their ability to make 
decisions?(Paper 3) 
The final component of shared decision-making that I explored in this dissertation 
project is role preference or desired role. The shared decision-making framework 
stipulates that an individual should be participating in the decision-making process at a 
level at which they are comfortable and willing. An evaluation of a patient’s willingness 
to participate in decision-making is critical so that providers can match their care with 
patient preferences157, whether those preferences are for shared decision-making, patient 
driven (active) or doctor driven (passive). Patients who are engaged in decision-making 
can have better outcomes and higher satisfaction with the decision-making process.25  
Desired role in the decision-making process is widely studied in the medical 
decision-making literature and in the context of colorectal cancer screening and evidence 
suggests that there is considerable variation in desired role by topic and sample. 
However, desired role in colorectal cancer screening has not been studied before in 
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individuals under age 50. In this study, I measured desired role in 3 ways: for general 
medical decisions, for deciding whether to get screened for CRC, and for which 
screening strategy to use. This study is also novel because I was able to measure the 
differences between the stable, general role preference and the situation specific role 
preferences.  
I found that the active role was preferred by participants most often for general 
medical decisions, deciding whether to get screened, and deciding which screening 
strategy to use. Participants’ role preference was stable from general medical decisions to 
the situation specific decisions 56.1%-84% of the time. In the multivariable, multinomial 
logistic regression models that I performed, I found that age was significantly associated 
with the decision for whether to get screened and which screening strategy to use. For 
both decisions, people under age 50 generally preferred a shared or passive role 
compared to an active role. This is contrary to findings in the literature that show that 
younger people generally prefer an active role in decision-making compared to their older 
counterparts.25 The preference for shared or passive role in younger people may be 
related to colorectal cancer not being on their ‘radar’ or not feeling that they have enough 
information to take an active role in making these decisions.  
Role preference may be important to consider if we incorporate people under age 
50 into colorectal cancer screening programs. Consistent public health messaging has 
ingrained the idea that screening should begin at age 50 so people younger than this may 
not have had the opportunity to process the need to make decisions about screening for 
themselves. Physicians will have to evaluate the best ways to match care with a patient’s 
desired role when working with individuals who are under age 50. This may require 
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researchers to develop and test tools that can be embedded into health systems that prime 
patients to think about these decisions and thus prepare them to take a more active role in 
their healthcare. Engaging these patients in the decision-making process can improve 
satisfaction with care and thus subsequent adherence to their chosen screening strategy. 
6.2 Common Elements Across Papers  
Age 
In all 3 manuscripts, I found age (<50) to be an important factor when evaluating 
the constructs of interest. In paper 1, age moderated the association between independent 
variables and knowledge of symptoms and risk factors; in paper 2, I found that age was 
associated with preferences for screening strategy; and in paper 3, age was associated 
with desired role in deciding whether to get screened and deciding which screening 
strategy to use. These findings are consistent with the primary motivation for conducting 
this project: to evaluate whether people under age 50 think differently about screening for 
CRC than people over age 50.  
There are several explanations for the differences that I found. First, colorectal 
cancer may not be on younger people’s ‘radar.103 Consistent public health messaging has 
focused on establishing and normalizing age appropriate, guideline-based screening for 
colorectal cancer. This messaging has focused on initiating screening starting at age 50. 
In this sense, younger people may see colorectal cancer as a disease of older age and, in 
many ways, this is a correct way of thinking. As age increases, the risk of developing 
CRC increases. However, age 50 is not a point in time where risk begins to dramatically 
increase, rather it is chosen as a time where the benefits versus burdens begin to shift in 
favor of population-based screening. In fact, when data are analyzed by year, many of the 
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cancers that are found at age 50 when people begin screening are likely already clinically 
significant well before age 50.124 Evidence from paper 1 points to another explanation: 
that people under age 50 process information about colorectal cancer differently than 
their older counterparts. We found that knowledge index scores for both symptoms and 
risk factors were not statistically different in both age groups, but the predictors of these 
scores varied by age. If this is the case, then incorporating younger people into screening 
programs may not be as simple as increasing their awareness of the importance of 
screening and putting the disease on their ‘radar’. It may involve identifying and targeting 
the moderating and mediating factors that differ in younger groups.  
Colorectal cancer represents the third highest mortality of cancer sites for both 
sexes.1 As an important cancer control priority, CRC has a large body of evidence 
exploring different facets of the disease and associated processes. As noted throughout 
this work, individuals under the age of 50 have not been traditionally included in research 
that evaluates colorectal cancer screening. Long standing guidelines have shaped research 
and the age samples that investigators have studied. Recent population-based analysis 
point to the steady rise in risk for CRC in individuals as young as 20. In fact, the risk is 
increasing the fastest for people in the youngest age brackets.8 These findings may push 
researchers to fill the gaps in knowledge for people younger than 50. In this project I 
evaluated perceptions that may be important for screening but there are numerous 
research questions yet to be unraveled in younger age groups across the cancer 
continuum related to concepts like etiology, diagnosis, survivorship, perceptions about 
CRC and disparities, among many others, along with the unique mediating and 
moderating factors that influence all of these. 
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Cancer Experience  
In this study, I collected variables such as whether the participant had ever been 
diagnosed with cancer, whether anybody close to the participant has died of cancer, if 
they knew anybody close to them who had ever been screened for CRC, commitment to 
testing for CRC, perceived likelihood of having cancer and how worried the participant 
was about cancer. These variables were associated with several of the key dependent 
variables that we evaluated in papers 1 and 3. In papers 1 and 3, the cancer experience 
variables were more highly associated with knowledge and role preference than most of 
the demographic variables that I measured. In breast cancer work, researchers have found 
that experience with cancer, such as death of a family member, predicts beliefs about 
screening more than family history alone.159 These results point to important contextual 
features that future work should assess when exploring perceptions about colorectal 
cancer screening in this age group.  
Heath Literacy 
 Health literacy and subjective numeracy are concepts that appear throughout 
cancer control research. In colorectal cancer, literacy and numeracy are related to a 
variety of concepts including knowledge160, attitudes,161 barriers to screening160, and 
perceptions of risk information161. These concepts also appear as themes throughout this 
project. In paper 1, higher numeracy was significantly associated with higher knowledge 
of risk factors and this relationship was moderated by age with the relationship remaining 
significant only in those under 50. In paper 2, lower health literacy was significantly 
associated with exclusion from the AHP exercise due to inconsistency and with the 
preference for CTC (the ‘middle option’). In paper 3, both literacy and numeracy were 
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associated with lower? decisional self-efficacy. Future work should evaluate both literacy 
and numeracy longitudinally in the context of shared decision-making to assess whether 
they facilitate or hinder patients’ decision-making processes.  
6.3 Study Limitations 
There are several limitations to note when interpreting the results of this 
dissertation. These are identified in each individual paper and will be summarized here in 
the context of the overall project. 
Sample racial/ethnic diversity 
A primary limitation of this dissertation is the racial and ethnic diversity of the 
sample that responded to the survey. Our sample was primarily female (61.8%), white 
(82.9%), insured by private insurance (67.9%), English speaking (99%), high health 
literacy (mean 17.8/20), high subjective numeracy (4.6/6), and married (48%). These 
demographic features are typical of MTurk samples138 and reflect the individuals that are 
taking research tasks through the MTurk platform. However, these demographic features 
are not reflective of an average community sample nor of those that are at highest risk of 
dying from colorectal cancer, namely those who are male and black.162 
 More recent work on young-onset colorectal cancer indicates that, among those 
under 50 diagnosed with CRC, Asians (10%), blacks (12%), and Pacific Islanders (45%)  
have higher odds of developing advanced stage disease. 163 Additionally, in the young 
onset age group (<50), those that are married have 11% lower odds of developing 
advanced CRC.163 Our sample was also not collected using clinical samples, however, I 
anticipate that the relationships that I found would be stronger in individuals that were 
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actively thinking and processing the colorectal cancer screening experience. This 
dissertation is a first step in evaluating the associations between age and perceptions of 
CRC and CRC screening. Because I have detected signals across several domains, future 
work should use targeted sampling to evaluate whether these associations remain stable 
for those at highest risk and for samples that are representative of an average community 
sample.  
Survey collection:  
This study is limited by its use of cross sectional, self-guided, online survey 
procedures. This limitation was noted across several aspects of the project. The cross-
sectional nature of the study did not allow us to explore beyond associations and it is 
difficult to determine the temporality of the associations that I did find. I consider the 
purpose of this project was not to prove causality, rather, I aimed to reveal associations 
that have not been studied before in people under age 50 to identify areas for more 
targeted evaluations.   Future work should evaluate whether these associations correspond 
to colorectal cancer screening behavior. 
 To collect the needed information to answer our research questions, I had to 
ensure that the survey was an appropriate length to keep participants engaged and to 
reduce respondent burden. This limitation was compounded by the impersonal nature of 
the MTurk platform that removes researcher-participant interaction. This meant that I had 
to exclude areas of interest in the survey to be sure that I was receiving high quality data 
for the primary research questions. Of note, if I were able to engage research participants 
in person, I would have liked to evaluate the unprompted assessments of colorectal 
cancer symptom and risk factor knowledge. An in-person evaluation would have also 
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allowed us to administer the original card-sorting control preferences scale.156 Finally, 
had I done an in-person assessment, I could have ran a guided session or used an 
interactive activity such as DefinitivePro149 for the AHP assessment. This may have 
reduced the number of participants that I had to exclude due to inconsistency.  Our online 
study excluded a lower proportion than Hummel, et al, who used a web-based survey for 
their AHP assessment. I excluded a larger proportion than Xu (2015), who used mail-in 
surveys with participants who had been previously engaged, and Dolan (2013), who used 
guided, in-person interviews.118 
6.4 Study Strengths 
The limitations that I have identified are balanced by several strengths. I have 
identified these strengths in each manuscript and will summarize in the following section 
in the context of the overall project. 
Sample Size 
I was able to recruit 579 individuals into this study using targeted convenience 
sampling through the MTurk platform at a relatively low cost compared to other survey 
research platforms. The large sample that I was able to recruit provided several 
advantages. First, this study was powered to detect the small effect sizes that we often see 
in psychological studies of behavioral constructs and processes. Second, the large sample 
size allowed me to include many variables in my multivariable models. Because I aimed 
to explore novel associations between variables, rather than build predictive models, 
controlling for many variables adds strengths to the associative conclusions that I made in 
each manuscript. Finally, I had power to study age subgroups. In both paper 1 and paper 
2, I split the sample into the two age subgroups and analyzed them separately. Without a 
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large sample size, the point-estimates in the multivariable models would have been 
unreliable. 
Sample Characteristics 
Despite the limitations mentioned above, using the MTurk platform allowed me to 
collect a large, national sample of participants who had never been screened for 
colorectal cancer before. Our sample represents individuals who may have not thought 
much about colorectal cancer and certainly those who do not have experience with the 
screening process. This is a strength of the study and we predict in more experienced 
samples, that the associations that we found would be stronger because they are actively 
processing their screening experience. The sample was diverse on several other 
characteristics besides race and ethnicity. We were able to recruit individuals from a 
range of income categories and individuals were spread relatively evenly among 
categorical income brackets with 19.3% of the sample making a household income of less 
than $30,000 and 25.7% making more than $90,000. Participants also represented a wide 
range of educational attainment levels, 16.6% had a high school education or less and 
22.3% had some graduate school or a graduate degree. Finally, we were able to recruit 
enough individuals who were uninsured (16.1%, n=93) and on public insurance (15.5%, 
n=90) to analyze these individuals as separate categorical groups. These demographics 
features are typical of average MTurk samples and similar scrutiny should be used when 




Robust collection of cancer experience variables  
As previously mentioned, this study is strengthened by the robust collection of 
cancer experience variables. Cancer experience variables are often left out of analysis in 
favor of demographic predictors. Including these variables in the multivariable models 
adds strength to the conclusions that I have drawn. We found associations that were 
highly significant across all three manuscripts, even when controlling for both 
demographic and cancer experience variables. This gives me confidence that the 
associations that I found are not spurious findings. 
6.5 Policy Implications 
Guideline Implications 
The Affordable Care Act mandates that insurance coverage, and thus, clinical care 
is guided by the recommendations of the United States Preventive Services Task Force,88 
rather than the recommendations made by the American Cancer Society. At the time of 
defending this dissertation (October 2020) the USPSTF has released their draft research 
plan to update their 2016 guidelines.165 It is unclear whether the updated recommendation 
will address colorectal cancer screening in individuals age 45-49 as the American Cancer 
Society guidelines did in 2018. Should the USTSPF also recommend screening in this 
age group, clinical practice and research will dramatically shift to accommodate these 
guidelines. 
The American Cancer Society guidelines for individuals age 45-49 are designated 
as ‘qualified’ recommendations. This is because research in this age group is lacking 
considerably to be able to accurately quantify the benefits and burdens associated with 
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screening in individuals under age 50. This dissertation provides evidence to begin 
exploring the details of screening in this population that has not been evaluated elsewhere 
in the literature. As evidence builds, the certainty around this recommendation will 
increase and give organizations that recommend policies more confidence in making 
recommendations to guide clinical care.  
Costs 
In paper 2, I found that people under 50 preferred colonoscopy as a screening 
strategy more often than people over the age of 50. This was due to their relative 
assignment of ‘features of the test’ compared to ‘test effectiveness’. While colonoscopy 
is generally considered the gold standard of colorectal cancer screening, it is also the 
costliest to perform and becomes more costly when you factor in age-based risk. 
Although all patients should be able to receive preference aligned care, there is no 
denying the costs associated with providing them with the most expensive option, 
especially if limited funds must be diverted from those at the highest risk. These findings 
align with the concerns of critics of expanding the screening age.13 In their 2019 paper, 
Ladabaum and colleagues showed that beginning colonoscopy screening starting at age 
45 is, indeed, cost effective.85 However, the resources used for additional colonoscopies 
in this age group could be used more efficiently by either: (1) providing colonoscopy 
every 10 years to unscreened individuals 55 years old; (2) providing colonoscopy 
screening every year to currently unscreened individuals 65 years old; or (3) increasing 
follow-up colonoscopy after abnormal FIT from 60%-90% in the current cohort of people 
who participate in yearly FIT screening. 85 Future work may need to explore the best way 
to reconcile preferences of younger individuals with the costs associated with their 
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preferred screening strategy should the age-preference associations that we found hold 
across studies. 
6.6 Clinical Implications 
These results also have clinical implications to consider. From the results of this 
study and prior work in this area we are developing an understanding that individuals 
under 50 may perceive colorectal cancer screening differently than their older 
counterparts. In this study, we explored the moderating role of age on knowledge, 
differences in screening strategy preferences, and different desired roles. Younger 
individuals also experience more social and practical problems in attaining 
colonoscopy91, low knowledge of available screening tests24, and financial strain in 
seeking colonoscopy92.The reasons for these differences have not yet been fully explored 
in the literature but this knowledge should be incorporated into clinical care when 
working with patients under age 50. Clinicians may need to use time and resources to 
evaluate knowledge more thoroughly and assess preferences and desired role. They also 
may need to modify clinical care to encourage shared decision making. Public health 
professionals need to incorporate messaging about young-onset colorectal cancer and 
encourage younger people to be vigilant about risk factors, symptoms, and screening for 
the disease. Researchers should develop resources for individuals who encounter social 
and practical problems and fill in the gaps in research for the clinical implications of 
younger age on CRC screening programs.  
There is also an opportunity to build interactive tools that encourage the shared 
decision-making process that can be embedded into a clinic’s or health system’s 
procedures. Activities such as the AHP exercise in Paper 2 can be evaluated as a tool to 
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encourage preference formulation that is key to the SDM process. An AHP activity could 
also be incorporated into larger tools that also address knowledge gaps or link patients to 
the resources that address their specific needs. Prior work has developed and tested tools 
that encourage shared decision making with some success in improving knowledge and 
intention to get screened but no tools to my knowledge have been specifically created to 
address the needs of younger individuals. Successful tools in this age group must 
addressed the unique challenges, knowledge gaps, and preferences of people under 50 
while paying special attention to some of the issues we have encountered in this study 
like literacy and numeracy. 
6.7 Conclusions  
In this dissertation, I have evaluated 3 key components of the shared decision-
making framework in the context of colorectal cancer screening in individuals under the 
age generally considered for age appropriate, guideline-based screening. The primary 
focus of this work was to determine whether people under age 50 think differently about 
colorectal cancer and its associated screening processes than people over age 50. I found 
in all 3 manuscripts that age was an important factor to consider. I found that age was a 
moderator to knowledge about risk factors and symptoms, was associated with 
preferences for screening tests, and was related to role preference in the decision-making 
process for deciding whether to get screened and deciding which screening test to choose.  
Screening for CRC in individuals under age 50 is a controversial topic in the 
research literature. At the time of defending this dissertation project, these practices have 
not currently been incorporated into regular clinical care. In this sense, this project is 
exploratory and preemptive in nature. However, we have already seen shifts in practice in 
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the months following these guideline recommendations.139 These findings will act as a 
foundation for future work if it becomes necessary to incorporate younger people into 




Appendix A: Data Collection Instrument  
 
 
Start of Block: Demographics 
 
Q1  
This is the beginning of your mTurk Task.  
 
 
After you have completed this task, you will be provided with your survey code. 
 
 
Page Break  
 




Q3 On your last birthday, how old did you turn? 







Q4 Are you Hispanic or Latino/a? 
o No, not Hispanic or Latino/a  (1)  
o Yes, Hispanic or Latino/a  (2)  
 
Q5 What country were you born in? 
o United States  (1)  







Q6 Is English your primary spoken language? 
o Yes  (1)  




Page Break  
 
Q7 What sex were you assigned at birth, on your original birth certificate? 
o Male  (1)  
o Female  (2)  
o Intersex  (3)  
 
Q8  
Which one of these terms do you identify with most? 
o Man  (1)  
o Woman  (2)  
o Transgender man  (3)  
o Transgender woman  (4)  






Sexual orientation is often used to describe who you are emotionally, romantically, 
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or sexually attracted to.     What one best describes your current sexual orientation?  
 
o Heterosexual/straight  (1)  
o Asexual  (2)  
o Bisexual  (3)  
o Lesbian/Gay  (4)  




Page Break  
 




Q11 What is the highest level of education you've completed? 
o 1st grade  (1)  
o 2nd grade  (2)  
o 3rd grade  (3)  
o 4th grade  (4)  
o 5th grade  (5)  
o 6th grade  (6)  
o 7th grade  (7)  
o 8th grade  (8)  
o 9th grade  (9)  
o 10th grade  (10)  
o 11th grade  (11)  
o 12th grade/GED  (12)  
o College freshman  (13)  
o College Sophomore/Associate's degree  (14)  
o College Junior  (15)  
o College completion  (16)  
o Some graduate school but no degree received  (17)  
o Master's degree  (18)  
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o Some professional school (such as law or medical school) but no degree received  
(19)  





Q12 Have you completed a technical or trade school program (such as beautician, 
cosmetology, mechanic, business, appliance repair, computer, etc.)? 
o No  (0)  
o Yes  (1)  
 
 
Page Break  
Q13 Think about the family members in your household who live with you right now. 
About how much income did you and your family members make in the last year before 
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taxes? (Include child support, cash payments and assistance from the government—for 
example, SNAP, TANF, SSI, or unemployment compensation) 
o Less than $10,000  (1)  
o $10,000 - $19,999  (2)  
o $20,000 - $29,999  (3)  
o $30,000 - $39,999  (4)  
o $40,000 - $49,999  (5)  
o $50,000 - $59,999  (6)  
o $60,000 - $69,999  (7)  
o $70,000 - $79,999  (8)  
o $80,000 - $89,999  (9)  
o $90,000 - $99,999  (10)  
o More than $100,000  (11)  
Q14 How many people are supported on this income? 
o 1 (just me)  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  










Page Break  
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Q17 Are you currently covered by any of the following types of health insurance or 
health coverage plans? 
 Yes (1) No (4) 
Insurance through a current or former 
employer or union (1)  o  o  
Insurance purchased directly from an 
insurance company (2)  o  o  
Medicare, for people 65 and older or people 
with certain disabilities (3)  o  o  
Medicaid (or MediCal in California), 
medical assistance, or any kind of 
government-assistance plan for those with 
low incomes or a disability (4)  
o  o  
TRICARE or other military health care (5)  o  o  
VA (including those who have ever used or 
enrolled for VA health care) (6)  o  o  
Indian Health Service (7)  o  o  
Any other type of health insurance or 






Q18 Describe your current relationship status. [Select the one best answer] 
o Single but dating  (1)  
o Single and not dating  (2)  
o In a committed relationship but unmarried  (3)  
o Legally married / domestic partnership  (4)  
o Living with a permanent partner but unmarried  (5)  
o In a committed relationship with multiple partners (if so, how many)  (6) 
________________________________________________ 
o Divorced  (7)  
o Widowed  (8)  






In general, would you say your health is... 
o Excellent  (1)  
o Very good  (2)  
o Good  (3)  
o Fair  (4)  
o Poor  (5)  
 
 
Page Break  
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Q20 Overall, how confident are you about your ability to take good care of your health? 
o Completely confident  (1)  
o Very confident  (2)  
o Somewhat confident  (3)  
o A little confident  (4)  
o Not confident at all  (5)  
 
 
Q21 Overall, how confident are you that you could get advice or information about health 
or medical topics if you needed it? 
o Completely confident  (1)  
o Very confident  (2)  
o Somewhat confident  (3)  
o A little confident  (4)  
o Not confident at all  (5)  
 
End of Block: Demographics 
 
Start of Block: Numeracy and Literacy 
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Q22 How confident are you filling out medical forms by yourself? 
o Extremely  (1)  
o Quite a bit  (2)  
o Somewhat  (3)  
o A little bit  (4)  




Q23 How often do you have someone help you read medical materials? 
o Always  (1)  
o Often  (2)  
o Occasionally  (3)  
o Sometimes  (4)  
o Never  (5)  
 
 
Q24 How often do you have problems learning about your medical condition   because of 
difficulty understanding written information? 
o Always  (1)  
o Often  (2)  
o Occasionally  (3)  
o Sometimes  (4)  




Q25 How often do you feel you don’t understand what the doctor tells you? 
o Always  (1)  
o Often  (2)  
o Occasionally  (3)  
o Sometimes  (4)  
o Never  (5)  
 
 
Page Break  
 
 
Q26 How good are you at working with fractions? 
o 1 Not at all good  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  





Q27   How good are you at working with percentages? 
o 1 Not at all good  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  




Q28  How good are you at calculating a 15% tip? 
o 1 Not at all good  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  





Q29     How good are you  at figuring out how much a shirt will cost if it is 25% off? 
o 1 Not at all good  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6 Extremely good  (6)  
 
 
Page Break  
 
 
Q30 When reading the newspaper, how helpful do you find tables and graphs that are 
parts of a story? 
o 1 Not at all helpful  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  





Q31 When people tell you the chance of something happening, do you prefer that they 
use words (eg. "it rarely happens") or numbers (eg. "there's a 1% chance")? 
o 1 Always prefer words  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  




Q32 When you hear a weather forecast, do you prefer predictions using percentages (e.g., 
“there will be a 20% chance of rain today”) or predictions using only words (e.g., “there 
is a small chance of rain today”)? 
o 1 Always prefer percentages  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  





Q33 How often do you find numerical information to be useful? 
o 1 Never  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6 Very often  (6)  
 
End of Block: Numeracy and Literacy 
 
Start of Block: Relationship with provider 
 
 
Q34 Not including psychiatrists and other mental health professionals, is there a 
particular doctor, nurse, or other health professional that you see most often? 
o No  (0)  
o Yes  (1)  
 
 
Display This Question: 
If Not including psychiatrists and other mental health professionals, is there a 
particular doctor,... = Yes 
 
133 
Q35 What kind of medical provider is this (the one you go to most frequently)? 
o Primary, family, or general care  (1)  
o OBGYN  (2)  
o Oncologist  (3)  
o Gastroenterologist  (4)  
o Dermatologist  (5)  




Display This Question: 
If Not including psychiatrists and other mental health professionals, is there a 
particular doctor,... = Yes 
 
Q36  
How would you describe your relationship with this provider? 
o Excellent  (1)  
o Very good  (2)  
o Good  (3)  
o Fair  (4)  
o Poor  (5)  
o Very poor  (6)  
 
 






In the past 12 months, not counting times you went to an emergency room, how many 
times did you go to a doctor, nurse, or other health professional to get care for yourself? 
o None  (1)  
o 1 time  (2)  
o 2 times  (3)  
o 3 times  (4)  
o 4 times  (5)  
o 5-9 times  (6)  





Q38 Overall, how would you rate the quality of health care you received in the past 12 
months? 
o Excellent  (1)  
o Very good  (2)  
o Good  (3)  
o Fair  (4)  







Some people avoid visiting their doctor even when they suspect they should. Would you 
say this is true for you or not true for you? 
o Not true  (0)  
o True  (1)  
 
End of Block: Relationship with provider 
 
Start of Block: RQ3: Control Preferences 
 
Q40 Which of the following best describes what you think when making decisions 
about your health: 
o I prefer to make the decision about which treatment I will receive  (1)  
o I prefer to make the final decision about my treatment after seriously considering 
my doctor’s opinion  (2)  
o I prefer that my doctor and I share responsibility for deciding which treatment is 
best for me  (3)  
o I prefer that my doctor makes the final decision about which treatment will be 
used, but seriously considers my opinion  (4)  
o I prefer to leave all decisions regarding treatment to my doctor  (5)  
 
 




Q41 Which of the following best describes what you think when making decisions 
about whether you should get screened for colorectal cancer: 
o I prefer to make the decision about whether I should get screened  (1)  
o I prefer to make the final decision whether I should get screened after seriously 
considering my doctor’s opinion  (2)  
o I prefer that my doctor and I share responsibility for deciding whether I should get 
screened  (3)  
o I prefer that my doctor makes the final decision about whether I should get 
screened, but seriously considers my opinion  (4)  
o I prefer to leave all decisions regarding whether I should get screened to my 
doctor  (5)  
 
 




Q42 Which of the following best describes what you think when making decisions 
about what screening test for colorectal cancer you should get: 
o I prefer to make the decision about what screening test I should get  (1)  
o I prefer to make the final decision about what screening test I should get after 
seriously considering my doctor’s opinion  (2)  
o I prefer that my doctor and I share responsibility for deciding what screening test I 
should get  (3)  
o I prefer that my doctor makes the final decision about what screening test I should 
get, but seriously considers my opinion  (4)  
o I prefer to leave all decisions regarding what screening test I should get to my 
doctor  (5)  
 
End of Block: RQ3: Control Preferences 
 





Below are listed some things involved in making an informed medical choice between 
several options. Please show how confident you feel in doing these things by answering 
the following questions:  On a scale of 1 to 5, with 1 being not confident at all and 5 




Not at all 
confident 
(1) (0) 




Get the facts about the 
options available to me (1)  o  o  o  o  o  
Get the facts about the 
benefits of each option (2)  o  o  o  o  o  
Get the facts about the risks 
and side effects of each 
option (3)  
o  o  o  o  o  
Get the best available care 
(4)  o  o  o  o  o  
Understand the information 
enough to be able to make a 
choice (5)  
o  o  o  o  o  
Ask questions without 
feeling dumb (6)  o  o  o  o  o  
Express my concerns about 
each option (7)  o  o  o  o  o  
Ask for advice (8)  o  o  o  o  o  
Figure out the option that 
best suits me (9)  o  o  o  o  o  
Get my test results as 
quickly as possible (10)  o  o  o  o  o  
Handle unwanted pressure 
from others in making my 
choice (11)  
o  o  o  o  o  
Let the clinic team know 
what's best for me (12)  o  o  o  o  o  
Delay my decision if I feel I 
need more time (13)  o  o  o  o  o  
 
 
End of Block: DSES before 
 
Start of Block: RQ1: Knowledge of Risk Factors 
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No (2) I don't know (3) 
Increased age (1)  o  o  o  
Obesity or Higher body mass 
index (BMI) (2)  o  o  o  
Exposure to the sun without 
sunscreen (3)  o  o  o  
A diet high in red or processed 
meats (4)  o  o  o  
Diabetes (5)  o  o  o  
Inflammatory bowel disease such 
as Irritable bowel disorder (IBD) 
(6)  
o  o  o  
Alcohol consumption (7)  o  o  o  
Exposure to violent video games 
(8)  o  o  o  
Smoking cigarettes or other 
tobacco products (9)  o  o  o  
A family member with colon or 
rectal cancer (10)  o  o  o  
 
 
End of Block: RQ1: Knowledge of Risk Factors 
 
Start of Block: Knowledge of Symptoms 
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Q45 Which of the following are likely symptoms of colon or rectal cancer? 
 Yes (1) No (2) I don't know (3) 
Blood when you 
wipe after using the 
bathroom (blood in 
your stool) (1)  
o  o  o  
Persistent abdominal 
pain (2)  o  o  o  
Persistent anemia 
(paleness, weakness, 
fatigue) (3)  
o  o  o  
Persistent 
indigestion or heart 
burn (4)  
o  o  o  
Unexplained weight 
loss (5)  o  o  o  
Frequent urges to 
urinate (6)  o  o  o  
Persistent changes in 
bowel habits 
(narrowing of stool, 
diarrhea, or 
constipation) (7)  
o  o  o  
Frequent headaches 
(8)  o  o  o  
 
 
End of Block: Knowledge of Symptoms 
 
Start of Block: AHP INTRODUCTION 
 
 






When considering the procedure:   
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When considering the procedure:   
    





When considering the procedure:   
    











When considering the preparation:   
    







When considering the preparation:   
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When considering the preparation:   
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When considering the convenience:   
    







When considering the convenience:   
    






When considering the convenience:   
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When considering the possibility for complications:   
    







When considering the possibility for complications: 
   
    







When considering the possibility for complications:   
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When considering the frequency of testing: 
 
 






When considering the frequency of testing: 
   
    







When considering the frequency of testing:   
    





Page Break  
 
 
















When considering the follow up possibility: 
   
    









When considering the follow up possibility:   
    





Page Break  
 
 
















When considering the test effectiveness: 
 
 






When considering the test effectiveness 
   
    




End of Block: RQ2: AHP preferred test for criteria 
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Start of Block: RQ2: AHP when considering the screening plan 
 
Q97  
Please read carefully. For the following question:   
    
Frequency of testing refers to how often you must get the test when your results come 
back normal    
    





When considering the screening plan:   
    
Which is more important for your decision: the possibility for follow-up or the 
frequency of testing? 
o Possibility for follow-up  (1)  
o Frequency of testing  (2)  
o They are equally important  (3)  
 
Skip To: End of Block If When considering the screening plan:   Which is more important 
for your decision: the possibility... = They are equally important 
 
 
Q99 On a scale from 1 - 9, how much more important? 
 
 
End of Block: RQ2: AHP when considering the screening plan 
 
Start of Block: RQ2: AHP when considering features of the test 
 
Q100  
When considering the features of the test :   
    
Which is more important for your decision, the possibility of complications or the 
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convenience of the test?   
  
o Possibility of complications  (1)  
o Convenience of the test  (2)  
o They are equally important  (3)  
 
Skip To: Q102 If When considering the features of the test :   Which is more important for 
your decision, the poss... = They are equally important 
 
 








When considering the features of the test :   
    
Which is more important for your decision, the possibility of complications or the 
procedure? 
o Possibility of complications  (1)  
o The procedure  (2)  
o They are equally important  (3)  
 
Skip To: Q104 If When considering the features of the test :   Which is more important for 
your decision, the poss... = They are equally important 
 
 









When considering the features of the test :   
    
Which is more important for your decision, the possibility of complications or the 
preparation? 
o Possibility of complications  (1)  
o The preparation  (2)  
o They are equally important  (3)  
 
Skip To: Q106 If When considering the features of the test :   Which is more important for 
your decision, the poss... = They are equally important 
 
 








When considering the features of the test :   
    
Which is more important for your decision, the convenience of the test or the 
procedure? 
o The convenience of the test  (1)  
o The procedure  (2)  
o They are equally important  (3)  
 
Skip To: Q108 If When considering the features of the test :   Which is more important for 
your decision, the conv... = They are equally important 
 
 









When considering the features of the test :   
    
Which is more important for your decision, the convenience of the test or the 
preparation? 
o The convenience of the test  (1)  
o The preparation  (2)  
o They are equally important  (3)  
 
Skip To: Q110 If When considering the features of the test :   Which is more important for 
your decision, the conv... = They are equally important 
 
 




Page Break  
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Q110  
When considering the features of the test :   
    
Which is more important for your decision, the procedure or the preparation? 
o The procedure  (1)  
o The preparation  (2)  
o They are equally important  (3)  
 
Skip To: End of Block If When considering the features of the test :   Which is more 
important for your decision, the proc... = They are equally important 
 
 
Q111 On a scale from 1 - 9, how much more important? 
 
 
End of Block: RQ2: AHP when considering features of the test 
 
Start of Block: RQ2: AHP when choosing a preferred test 
 
Q112  
We are now going to ask you a few questions about the most important things for you to 
make a decision about choosing your preferred test.   










Please read carefully. For the following questions you will rate the following on which 
is most important for your decision to choose a preferred test:   
    
 Test effectiveness refers to the tests effectiveness     Features of the test refers to the 
procedure, the preparation, the convenience of the test, and the possibility for 









 When choosing a preferred test: 
Test effectiveness refers to the tests effectiveness 
Screening plan refers to frequency of testing, and the follow up possibility   
    
Which is more important for your decision, test effectiveness or the screening plan? 
o Test effectiveness  (1)  
o The screening plan  (2)  
o They are equally important  (3)  
 
Skip To: Q116 If When choosing a preferred test: Test effectiveness refers to the tests 
effectiveness Screening pl... = They are equally important 
 
 








When choosing a preferred test:   
    
  
 Screening plan refers to frequency of testing, and the follow up possibility     Features 
of the test refers to the procedure, the preparation, the convenience of the test, and the 
possibility for complications     
    
Which is more important for your decision, the screening plan or the features of the 
test? 
o The screening plan  (1)  
o Features of the test  (2)  
o They are equally important  (3)  
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Skip To: Q118 If When choosing a preferred test:   Screening plan refers to frequency of 
testing, and the follow u... = They are equally important 
 
 








When choosing a preferred test: 
 
 
Features of the test refers to the procedure, the preparation, the convenience of the test, 




Test effectiveness refers to the tests effectiveness   
    
Which is more important for your decision, the features of the test or test effectiveness? 
o Features of the test  (1)  
o Test effectiveness  (2)  
o They are equally important  (3)  
 
Skip To: End of Block If When choosing a preferred test: Features of the test refers to the 
procedure, the preparation, th... = They are equally important 
 
 
Q119 On a scale from 1 - 9, how much more important? 
 
 
End of Block: RQ2: AHP when choosing a preferred test 
 
Start of Block: Test choice actual 
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Q120 After completing this exercise, which test for colorectal cancer would you choose? 
o CTC  (1)  
o FIT  (2)  
o Colonoscopy  (3)  
o I would not choose any of these tests  (4)  
 
 
Display This Question: 
If After completing this exercise, which test for colorectal cancer would you choose? 
= CTC 
Or After completing this exercise, which test for colorectal cancer would you 
choose? = FIT 
Or After completing this exercise, which test for colorectal cancer would you 
choose? = Colonoscopy 
 








Display This Question: 
If After completing this exercise, which test for colorectal cancer would you choose? 
= I would not choose any of these tests 
 
Q122 Why would you not choose any of these tests? 
________________________________________________________________ 
 
End of Block: Test choice actual 
 
Start of Block: RQ3: Control preferences After 
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Q123 Which of the following best describes what you think when making decisions 
about your health: 
o I prefer to make the decision about which treatment I will receive  (1)  
o I prefer to make the final decision about my treatment after seriously considering 
my doctor’s opinion  (2)  
o I prefer that my doctor and I share responsibility for deciding which treatment is 
best for me  (3)  
o I prefer that my doctor makes the final decision about which treatment will be 
used, but seriously considers my opinion  (4)  
o I prefer to leave all decisions regarding treatment to my doctor  (5)  
 
 




Q124 Which of the following best describes what you think when making decisions 
about whether you should get screened for colorectal cancer: 
o I prefer to make the decision about whether I should get screened  (1)  
o I prefer to make the final decision whether I should get screened after seriously 
considering my doctor’s opinion  (2)  
o I prefer that my doctor and I share responsibility for deciding whether I should get 
screened  (3)  
o I prefer that my doctor makes the final decision about whether I should get 
screened, but seriously considers my opinion  (4)  
o I prefer to leave all decisions regarding whether I should get screened to my 
doctor  (5)  
 
 
Page Break  
 
 
Q125 Which of the following best describes what you think when making decisions 
about what screening test for colorectal cancer you should get: 
o I prefer to make the decision about what screening test I should get  (1)  
o I prefer to make the final decision about what screening test I should get after 
seriously considering my doctor’s opinion  (2)  
o I prefer that my doctor and I share responsibility for deciding what screening test I 
should get  (3)  
o I prefer that my doctor makes the final decision about what screening test I should 
get, but seriously considers my opinion  (4)  
o I prefer to leave all decisions regarding what screening test I should get to my 
doctor  (5)  
 




Below are listed some 
things involved in making 
an informed medical 
choice between several 
options. Please show how 
confident you feel in 
doing these things by 











Get the facts about the 
options available to me 
(1)  
o  o  o  o  o  
Get the facts about the 
benefits of each option (2)  o  o  o  o  o  
Get the facts about the 
risks and side effects of 
each option (3)  
o  o  o  o  o  
Get the best available care 
(4)  o  o  o  o  o  
Understand the 
information enough to be 
able to make a choice (5)  
o  o  o  o  o  
Ask questions without 
feeling dumb (6)  o  o  o  o  o  
Express my concerns 
about each option (7)  o  o  o  o  o  
Ask for advice (8)  o  o  o  o  o  
Figure out the option that 
best suits me (9)  o  o  o  o  o  
Get my test results as 
quickly as possible (10)  o  o  o  o  o  
Handle unwanted pressure 
from others in making my 
choice (11)  
o  o  o  o  o  
Let the clinic team know 
what's best for me (12)  o  o  o  o  o  
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Delay my decision if I 
feel I need more time (13)  o  o  o  o  o  
 
 
End of Block: DSES after new 
 
Start of Block: Family experience with cancer 
 
Q127  
In general, would you say your health is... 
o Excellent  (1)  
o Very good  (2)  
o Good  (6)  
o Fair  (7)  





How important is it that you are screened for any of the types of cancer listed below in 
your lifetime?   
    
 Please be sure to indicate the importance for each type of cancer by moving the slider 
to the right   
  
 Extremely unimportant Extremely important 
 
 0 10 20 30 40 50 60 70 80 90 100 
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Skin cancer () 
 
Lung cancer () 
 
Colon or rectal cancer () 
 
Human-Papilloma (HPV) Related (anal, 
penile, cervical or head and neck) ()  
Breast cancer () 
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It seems like 
everything 
causes cancer (1)  
o  o  o  o  
There's not much 
you can do to 
lower your 
chances of 
getting cancer (2)  
o  o  o  o  




cancer, it's hard 
to know which 
ones to follow 
(3)  









How likely are you to get cancer in your lifetime? 
   
  
o Very unlikely  (1)  
o Unlikely  (7)  
o Neither unlikely nor likely  (8)  
o Likely  (9)  
















How worried are you about getting cancer? 
o Not at all  (1)  
o Slightly  (2)  
o Somewhat  (3)  
o Moderately  (4)  
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Q135 Have you ever been diagnosed as having cancer? 
o No  (1)  




Q136 Have any of your family members ever been diagnosed as having cancer? 
o No  (1)  
o Yes (what type)  (2) ________________________________________________ 






Q137 Has anybody close to you ever died of cancer? 
o No  (0)  
o Yes  (1)  
 
Skip To: Q140 If Has anybody close to you ever died of cancer? = No 
 
 













In your family or culture, are there any beliefs or values that influence how you think 
about cancer? 
 
o No  (1)  
o Yes  (2)  
 
 
Display This Question: 
If In your family or culture, are there any beliefs or values that influence how you 
think about can... = Yes 
 














Q142 Has your partner or spouse ever gotten tested for colon or rectal cancer? 
o No  (0)  
o Yes  (1)  





Q143 Has your parent or guardian ever gotten tested for colon or rectal cancer? 
o No  (0)  
o Yes  (1)  





Q144 Has anybody else close to you ever gotten tested for colon or rectal cancer? 
o No  (0)  
o Yes  (1)  
o I don't know  (2)  
 
 
Display This Question: 
If Has anybody else close to you ever gotten tested for colon or rectal cancer? = Yes 
Or Has your parent or guardian ever gotten tested for colon or rectal cancer? = Yes 
Or Has your partner or spouse ever gotten tested for colon or rectal cancer? = Yes 
 









Display This Question: 
If Has anybody else close to you ever gotten tested for colon or rectal cancer? = Yes 
Or Has your parent or guardian ever gotten tested for colon or rectal cancer? = Yes 
Or Has your partner or spouse ever gotten tested for colon or rectal cancer? = Yes 
 
Q146 What test(s) did they get? 
▢ Colonoscopy  (1)  
▢ Sigmoidoscopy  (2)  
▢ Fecal blood test  (3)  
▢ Fecal DNA test  (4)  
▢ Computed tomography colonography (CTC)  (5)  
▢ Double contrast barium enema  (6)  
▢ ⊗I don't know  (7)  





Q147 Which statement is closest to where you are now in your plans to get a screening 
test for colon or rectal cancer? 
o I have not thought about getting tested  (1)  
o I think I need to consider getting tested  (2)  
o I think I should get tested but I'm not quite ready  (3)  
o I think I will probably get tested  (4)  
o I am committed to getting tested  (5)  
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Q150 On your last birthday, how old did you turn? 









Q151 Please enter your mTurk worker ID 
________________________________________________________________ 
 









1. Information about colorectal cancer and screening for colorectal cancer 
 
“Here is some information about colorectal cancer that we would like you to read:   
 
• Colorectal cancer occurs when cell overgrowth occurs in the parts of the large 
intestine known as the colon or rectum.         
• Development of colorectal cancer begins as a noncancerous growth or 
precancerous lesion, called polyps.  
• Polyps are found in up to 30 to 40% of people by age 60 but only ~10% of polyps 
progress to cancer.     
• However, over 95% of colorectal cancers begin as polyps.  
• Polyps can develop into cancer over a period of 10 to 20 years.  
• This is why screening for colorectal cancer is important 
• We are now going to have you read about 3 options for colorectal cancer 
screening and answer questions about your preferences” 
 
2. Descriptions of screening strategies 
A. Test effectiveness: 
Colonoscopy… 
Effectiveness As a screening plan can reduce mortality by 
up to 85% over your lifetime  
Prevention Can detect polyps before they turn into 
cancer 
Removal Can remove polyps or cancer during the 
procedure 
False-positive Very unlikely to have an abnormal test if you 








Fecal immunochemical test (FIT)… 
Effectiveness As a screening plan can reduce mortality by up 
to 78% over your lifetime 
Prevention Can detect polyps before they turn into cancer if 
they are bleeding 
Removal Cannot remove polyps or cancer as part of the 
procedure 
False-positive Possible to have an abnormal test even if you 
do not have polyps or cancer 
 
Computed tomography colonography (CTC)… 
Effectiveness As a screening plan can reduce mortality by up 
to 80% over your lifetime 
Prevention Can detect polyps before they turn into cancer 
Removal Cannot remove polyps or cancer as part of the 
procedure 
False-positive Possible to have an abnormal test even if you 
do not have polyps or cancer 
 
*Note: Mortality reduction estimates are derived from the CISnet modeling studies 
(participants not provided this reference) 
Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of 
colorectal cancer screening strategies: modeling study for the US Preventive Services 
Task Force. JAMA. 2016;315:2595‐2609. 
 
B. Screening plan:  




No additional follow up procedures are 
required 
Polyps  If polyps are found, they are removed and 
examined for cancer 
Cancer  If cancer is suspected you will be referred to a 
specialist 
 
Fecal immunochemical test (FIT)… 
Follow up procedure If the test is not normal and blood is 
detected in your stool, you must get a 
follow up colonoscopy 
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Polyps  This test cannot confirm polyps, only a 
colonoscopy can confirm polyps 
Cancer  This test cannot confirm cancer, only a 
colonoscopy can confirm cancer 
 
Computed tomography colonography (CTC)… 
Follow up procedure If your test is not normal, you must get a 
colonoscopy 
Polyps  This test cannot confirm polyps, only a 
colonoscopy can confirm polyps 
Cancer  This test cannot confirm cancer, only a 
colonoscopy can confirm cancer 
 
ii. Frequency of testing: 
Colonoscopy… 
Normal result You should be tested again in 10 years 
 
Fecal immunochemical test (FIT)… 
Normal result You should be tested again in 1 year 
 
Computed tomography colonography (CTC)… 
Normal result You should be tested again in 5 years  
 
C. Features of the test:  
i. Possibility for complications: 
Colonoscopy… 




Rare and include: major bleeding (requiring hospitalization or 
transfusion), adverse reaction to sedation, and perforation 
(tearing a hole) in your colon 




Fecal immunochemical test (FIT)… 
Minor risks Uneasiness or anxiety from handling stool 
Serious complications Has no serious complications 
Increased risk None 
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Computed tomography colonography (CTC)… 
Minor risks Cramps, bloating or gas 
Serious complications Extremely rare and include: potential development of 
radiation related cancer 




Where Must be done at a doctors office 
Driver You must have somebody to drive you home  
 
Work You must take a day off of work  
 
Fecal immunochemical test (FIT)… 
Where Is done at home 
Driver Does not require somebody to drive you 
home  
Work Does not require you to take a day off work 
 
Computed tomography colonography (CTC)… 
Where Must be done at a doctors office 
Driver Does not require somebody to drive you 
home 




Diet No food or liquids starting the day 
before your test 
Laxative Drink a total of 64oz of laxative 
medication starting the day before your 
test to clean out your colon 
Bowel 
cleanliness 
Laxatives will make you use the 
restroom until your bowels are clear 
 
Fecal immunochemical test (FIT)… 
Diet There are no dietary restrictions 
Laxative There is no laxative medication 
Bowel 
cleanliness 




Computed tomography colonography (CTC)… 
Diet No food or liquids starting the day 
before your test 
Laxative Drink a total of 64oz of laxative 
medication starting the day before your 
test to clean out your colon 
Bowel 
cleanliness 
Laxatives will make you use the 




Method  Performed by a doctor who inserts a scope is into 
your anus to view the entire colon 
Sedation Sedation is given to reduce or eliminate discomfort 
Time for 
procedure 
20-30 minutes for the procedure  
Recovery A recovery period (approximately 30-60 minutes) 
is necessary because of the sedation you receive 
Purpose Allows a doctor to visualize the lining of the whole 
colon to look for polyps or cancer 
 
Fecal immunochemical test (FIT)… 
Method Requires you to use a mini brush to collect stool into a 
tube at home that you mail in for testing 




Recovery No recovery 
Purpose Detects microscopic blood in your stool which may be 
from polyps or cancer 
 
Computed tomography colonography (CTC)… 
Method Performed by a doctor and requires that you to lay in 
a CT scanner after drinking a contrast liquid and 
having air pumped into your anus using a small tube 




Recovery No recovery 
Purpose Allows a doctor to use a CT scanner to make pictures 
of your whole colon and detect any polyps or cancer 
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Appendix C: IRB Documents 
 
INITIAL APPLICATION PART 2 
 
1. Abstract:   
 
Recent work using the Surveillance, Epidemiology, and End Results (SEER) 
database indicates that the rates for colon and rectal cancer are increasing at an 
alarming rate in individuals under the age of 50. Because of this, The American 
Cancer Society gave a qualified recommendation for average risk adults to initiate 
colorectal cancer (CRC) screening at age 45. While a large body of literature on 
CRC screening exists, very few studies have focused on individuals under the age 
of 50 due to the previous, relative consensus on guidelines. In this dissertation I 
will explore research questions related to shared decision-making for colorectal 
cancer for people at average risk between the ages of 45 and 49 by recruiting 600 
people age 45 to 55 using the Amazon MTurk system. MTurk is a crowdsourcing 
system that has been shown to be effective for collecting large amounts of reliable 
and valid research data. 
 
I will answer the following research questions: 
RQ1: Are people ages 45 to 49 able to correctly identify risk factors of CRC? 
RQ2: What tests do individuals ages 45 to 49 prefer and what are these 
preferences based on? 
RQ3: When making CRC screening decisions, what level of control (role 
preference) do people ages 45 to 49 prefer and do they feel confident in their 
ability to make decisions? 
 
2. Subject Selection: 
 
a. Recruitment: For this study, we plan to enroll adults age 45-55. Participants will 
be recruited through the Amazon Mechanical Turk (MTurk) system, a global 
workforce of people who complete tasks for compensation. Previous research 
using the MTurk population indicates that they provide reliable and valid data for 
survey research.  
 
This study will screen for individuals living in the United States, mTurk worker 
qualifications, and age 45-55 using the mTurk system. 
 
We will also screen to ensure that participants have never been screened for CRC. 
Additionally, the Qualtrics quota function will be used to ensure that age 
categories are even (45-49 and 50-55) and we will oversample for black/African 
American participants to ensure that we have power to detect differences in the 
highest risk race group. 
 
Workers will self-select into this study by selecting (clicking) on the task 
containing the survey. After completing screening questions, eligible participants 
will proceed with the rest of the survey. Ineligible participants will be asked to 
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return the task per the task instructions that are provided in this IRB package 
(recruitment page and instructions). Once the quota for each category is filled, 
subsequent participants will be ineligible (not eligible message). 
 
 
b. Eligibility Criteria:  Eligibility criteria for the study include: age 45-55, living in 
the United States, able to adequately read and answer question in English, over 
500 approved mTurk tasks, >95% mTurk task approval rating and never been 
screened for colon or rectal cancer. 
 
The literature shows that setting eligibility criteria around mTurk worker features 
lead to higher quality data. That is why workers must have 500 completed and 
approved tasks with a >95% approval rating. We are requiring that participants 
have never been screened for colon or rectal cancer because many of the attitudes 
towards screening that we are measuring will be influenced by prior experience 
with the screening tests.  
 
 
c. Rationale: The mTurk literature shows that placing restrictions around the 
minimum number of tasks and task approval rating lead to higher quality research 
data. All mTurk workers must be at least 18 years old and our survey will be 
conducted in English. 
 
Participants must have never been screened for colon or rectal cancer because our 
primary research questions are around perceptions of screening exams that would 
be different in a sample that has already been screened.  
 
d. Enrollment Numbers: The total enrollment for this study is 600 people in the 
final sample and 30 people for a pilot test.  
 
e. Rationale for Enrollment Numbers: For RQ 1 and RQ3, in order to detect a 
small effect size (.2) using a linear regression, with .05 alpha, .2 beta and 8 
predictors, I would need approximately 84 individuals in my sample. In order to 
detect a small effect size using logistic regression (OR=1.7), with .05 alpha, and 
.2 beta, I would need 184 individuals in my sample. However, because I am using 
a fixed sample of 600 individuals, I performed a sensitivity analysis using similar 
parameters to calculate the effect sizes that I could detect based on the sample size 
of 600. For logistic regression, I could detect an odds ratio of 1.33. For linear 
regression, I could detect an effect size of .02, which makes this study highly 





We will conduct a pilot test with 30 mTurk workers to ensure that our survey 
measures are working as intended and that participants are able to complete 
measures with adequate accuracy and validity. The pilot test will be conducted 
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exactly the same as the full survey launch. Data from the pilot test will not be 
analyzed with the final sample.  
 
Full Survey Launch: 
Participants will select our task (HIT) from a list of available tasks on the MTurk 
platform (recruitment page and instructions). Participants will accept the task for 
the survey, read the consent document and give informed consent with a click. 
Participants who choose not to give consent will be thanked for their time.  
Participants that do give consent will then complete screening questions related to 
previous screening for CRC, race, sex, and age group 
(Thyams_CRC_screening_dissertation-1 IRB). 
 
If eligible, participants will continue to complete the full survey 
(Thyams_CRC_screening_dissertation-1 IRB)  Ineligible participants will be 
thanked for their time and asked to return the task as described in the instructions 
for accepting the task (recruitment page and instructions). 
 
The survey will cover demographics, history and experience with cancer, 
preferences for screening tests, and knowledge/desired role in decision-making 
about screening for colon and rectal cancer. At the end of the survey, participants 
will be provided with a random code that they will use to paste into a text-box in 
the MTurk platform. (end of survey message) This code will be utilized to verify 
that the participant has completed the survey by matching the code with the one 
provided by Qualtrics. Participants who provide matching codes will be 
compensated for their work. Workers will be compensated approximately $4.00 
for completion of the survey (15-20 minutes) at a living wage of approximately 
$15.00/hour. Final payment will be determined after an initial pilot test of 30 





This survey will ask questions about sensitive topics including past history with 
cancer, perceptions about cancer screening, and decisions around screening for 
cancer. Participants may feel uncomfortable or embarrassed answering these 
questions. However, participants will be informed, and voluntariness of questions 
will be reiterated so participants can be sure that they may skip questions that they 
do not wish to answer. Additionally, they can choose to discontinue the survey at 




We do not anticipate any direct benefits from study participation. Results from the 
analysis of these data will help inform potential changes to colorectal cancer 
screening programs that incorporate individuals between 45-49. If differences are 
found in knowledge and preferences in these age groups, screening programs can 





This study will not collect any Personally identifiable information such as names 
or address. We will collect zip code data but there will be no way to link these 
data to individuals. Qualtrics survey data will be password protected and requires 
the UMD multi-factor identification to log in. Data will be stored in the Qualtrics 
data base until downloaded by the investigators onto a password protected device. 
Only the investigators of this study that have been approved by the IRB will have 
access to raw data. 
 
Payment will be provided through a randomized confirmation code at the end of 
the survey. When participants enter this code into the MTurk system, the provided 
code and entered code will be compared. If the information matches, participants 
will be provided compensation for their work. MTurk allows you to set the 
amount of time it will take for workers to be paid automatically (without code 
comparison). We will set this time to 7 days to give our research staff enough 
time to compare worker codes and approve payment. 
 
The MTurk system provides each individual worker with a unique identification 
code (Worker ID). In theory, this ID could be linked to a worker’s public Amazon 
account which may contain personal information. To safeguard against this, the 
investigators will only use the worker ID to accurately provide payment to 
workers after survey completion. Once the worker is paid, the confirmation code 
will be deleted from the data set. The MTurk system allows you to contact 
workers after they complete your task through the system through email. We will 
not be contacting workers after they submit responses.  
 
To ensure that people are only allowed to take the survey one time, a script will 
be embedded into the MTurk survey builder from 
(https://uniqueturker.myleott.com/.). This script will block individuals who 
attempt to take the survey multiple times.  
 
 
7. Consent Process: 
 
Since there is no more than minimal risk (section 4) involved, we will utilize a 
modification of informed consent for this study. Participants will click to consent 
in lieu of a written signature. The informed consent text can be found within the 
survey attached to this IRB package (Thyams_CRC_screening_dissertation-1 
IRB). This document can be found as supplemental material in this IRB package. 
This document will appear in the main survey, before participants answer any 
questions. 
 
 This survey asks about sensitive questions. However, participants will be given 
several notifications that all questions are voluntary and that they may stop at any 
time. Participants will read a document about the risks and benefits of the study 
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and will click to give consent instead of signing a consent document.  
 
A consent modification is appropriate given the following rationale: 
 
1. There is no more than minimal risk to participants. They may feel 
uncomfortable answering questions, but they will be encouraged to skip any 
questions that they do not feel comfortable answering.  
 
2. A click consent will also not adversely affect the rights and welfare of the 
research participants. This is because any information linking their data to their 
Amazon profile will be deleted once they have been provided payment.  
 
3. A click consent, rather than a signed consent document is appropriate given the 
online nature of this work, and the efficient work-environment that the MTurk 
users are working in. Obtaining a signature for consent would be inefficient and 
impractical for these workers. 
 
4. There is no deception used in this study. We have no need to withhold, or give 
false or misleading information to participants in order to complete this study. 
 
8. Conflict of Interest: 
  
No conflicts of interest to report 
 
9. HIPAA Compliance: 
 
This research is HIPAA compliant because it will not collect any personally 
identifiable health information 
 








12. SUPPORTING DOCUMENTS 
 
Your Initial Application must include a completed Initial Application Part 1 (On-
Line Document), the information required in items 1-11 above, and all relevant 
supporting documents including: consent forms, letters sent to recruit 
participants, questionnaires completed by participants, and any other material 
that will be presented, viewed or read to human subject participants. 
 
 
The consent forms in your approved IRBNet PACKAGE must be used.  
When creating or editing your consent form, please provide the most 
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recent IRBNet package number at the bottom, right corner of the consent 
form.  This ensures you are using the most “up-to-date” version of the 
form.   
 
To find your IRBNet package number, go to the MY PROJECTS tab and 
click on the title of your project. In the PROJECT OVERVIEW page, your 
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